Antibody	Antibody binding type	PDB or other structure	Donor	Clonal lineage	Isolation paper(Pubmed ID)	Neutralizing antibody feature	Germline paper(Pubmed ID)	Germline software & DB	Heavy V (IGHV)	Heavy D (IGHD)	Heavy J (IGHJ)	Heavy CDR3 length	Heavy CDR3 seq	Light V (IGKV or IGLV)	Light J (IGKJ or IGLJ)	Light CDR3 length	Light CDR3 seq	Light chain type	LANL comments
10-1074	gp120 V3	4FQ2(10-1074 Fab);5T3X(Fully and Natively Glycosylated BG505 SOSIP.664 HIV-1 Env Trimer in Complex with Antibodies IOMA and 10-1074);5T3Z(Fully and Natively Glycosylated BG505 SOSIP.664 HIV-1 Env Trimer in Complex with Antibodies IOMA and 10-1074)	Donor 17 	PGT121	Mouquet2012a(23115339) 	10-1074 signature predictions (West2013);Key sites for PGT121-like and 10-1074-like mAbs	Mouquet2012a(23115339) 	IgBlast IMGT/V-QUEST	4-59*01	3-3 or 16	6*03	24	ARRGQRIYGVVSFGEFFYYYSMDV	3-21*02	3*02	12	HMWDSRSGFSWS	L	 
10-1074-IgG3C	gp120 V3		Donor 17 		Bournazos2016(27315478) 														IgG3C hinge variant 
10-1074V	gp120 V3		Donor 17 																 
10-996	gp120 V3		Donor 17 	PGT121	Mouquet2012a(23115339) 	10-996 signature predictions (West2013);Key sites for PGT121-like and 10-1074-like mAbs	Mouquet2012a(23115339) 	IgBlast IMGT/V-QUEST	4-59	3-3 or 10	6	24	TQQGKRIYGVVSFGEFFHYYYMDA	3-21*02	3*02	12	HKWDSRSPLSWV	L	 
10A3	gp120 V3		uncoded_rabbit 																rabbit antibody 
10A37	gp120 V3		uncoded_rabbit 																rabbit antibody 
10E8	gp41 MPER (membrane proximal external region)	4U6G(10E8 Fab in complex with a hydrocarbon-stapled HIV-1 gp41 MPER peptide);5IQ7(10E8-S74W Fab in complex with an HIV-1 gp41 peptide);5IQ9(10E8v4 Fab in complex with an HIV-1 gp41 peptide);4G6F(Fab 10E8 complexed with gp41 peptide)	Donor N152 	10E8	Huang2012a(23151583) 	10E8 contacts;10E8 residue prediction;10E8 signature predictions (West2013)	Huang2012a(23151583) 	IMGT/V-QUEST	3-15*05	3-3*01	1*01	22	TGKYYDFWSGYPPGEEYFQD	3-19*01	3*02	12	SSRDKSGSRLSV	L	 
10E8-0fH/0fL	gp41 MPER (membrane proximal external region)		Donor N152 	10E8	Georgiev2014(24391217) 														 
10E8-0fH/4fL	gp41 MPER (membrane proximal external region)		Donor N152 	10E8	Georgiev2014(24391217) 														 
10E8-10fH/10fL	gp41 MPER (membrane proximal external region)		Donor N152 	10E8	Georgiev2014(24391217) 														 
10E8-10fH/16fL	gp41 MPER (membrane proximal external region)		Donor N152 	10E8	Georgiev2014(24391217) 														 
10E8-10fH/4fL	gp41 MPER (membrane proximal external region)		Donor N152 	10E8	Georgiev2014(24391217) 														 
10E8-19fH/10fL	gp41 MPER (membrane proximal external region)		Donor N152 	10E8	Georgiev2014(24391217) 														 
10E8-19fH/16fL	gp41 MPER (membrane proximal external region)		Donor N152 	10E8	Georgiev2014(24391217) 														 
10E8-2fH/0fL	gp41 MPER (membrane proximal external region)		Donor N152 	10E8	Georgiev2014(24391217) 														 
10E8-2fH/10fL	gp41 MPER (membrane proximal external region)		Donor N152 	10E8	Georgiev2014(24391217) 														 
10E8-2fH/4fL	gp41 MPER (membrane proximal external region)		Donor N152 	10E8	Georgiev2014(24391217) 														 
10E8V1.1/P140			Donor N152 		Huang2016(27315479) 														bispecific 
10E8V2.0/iMab			Donor N152 		Huang2016(27315479) 														bispecific 
10J4			Donor N152 	35O22	Huang2014(25186731) 		Huang2014(25186731) 	IMGT/V-QUEST	1-18*02	5-24*01	4*02 or 4*03	16	GLLRDGSSTWLPHL	2-14*02	1*01	10	CSYTHNSGCV	L	 
10M6			Donor N152 	35O22	Huang2014(25186731) 		Huang2014(25186731) 	IMGT/V-QUEST	1-18*02	5-24*01	4*02 or 4*03	16	GLLRDGSSTWLPHL	2-14*02	1*01	10	CSYTHNSGCV	L	 
12A12	gp120 CD4BS		Patient 12 	12A12	Scheid2011(21764753) 	12A12 signature predictions (West2013)	Scheid2011(21764753) 		1-2	1-26 or 3-10	4 or 5	13	DGSGDDTSWHLDP	1D-33	3	5	AVLEF	K	 
12A21	gp120 CD4BS	4JPW(12a21 in complex with 93th057 gp120 mutant)	Patient 12 	12A12	Scheid2011(21764753) 	12A21 alanine scanning	Scheid2011(21764753) 		1-2	5-12 or 3-10	4 or 5	13	DESGDDLKWHLHP	1D-33	3	5	AVFQW	K	 12A21 is a close clonal relative of 12A10 and 12A4, and the germline repertoir is as shown for 12A4 in Scheid2011.
							Zhou2013a(23911655) 	IgBlast IMGT/V-QUEST	1-02*02			13	DESGDDLKWHLHP	1-33*01	1*01	5	AVFQW		
1357	gp120 V2		donor_uncoded_1 		Nyambi1998(9765494) 														 
1361	gp120 V2		donor_uncoded_1 		Nyambi1998(9765494) 														 
1393A	gp120 V2		donor_uncoded_1 		Nyambi2000(10888650) 														 
13I10			Donor N152 	35O22	Huang2014(25186731) 		Huang2014(25186731) 	IMGT/V-QUEST	1-18*02	5-24*01	4*02 or 4*03	16	GLLRDGPSTWLPHL	2-14*02	1*01	10	CSYTHNSGCV	L	 
15e	gp120 CD4BS		N70 		Robinson1990c(1694449) 		Gorny2009(18952295) 		4-39*02	2-8	6								 
179NC75	gp120 CD4BS		EB179 		Freund2015(26516768) 	179NC75 key sites	Freund2015(26516768) 	IgBlast IMGT/V-QUEST	3-21	3-9	5	24	VHAWRYFDWVNRRSPVEKVLSIDL	3-1	2	10	QTWDSKNYVT	L	 
17b	gp120 CD4i CoRBS (Cluster C)	1RZ8(antibody 17b);1YYL(CD4M33, a scorpion-toxin mimic of CD4, in complex with gp120 (YU2) and 17b);2I5Y(CD4M47, a scorpion-toxin mimic of CD4, in complex with gp120 (YU2) and 17b);1YYM(F23, a scorpion-toxin mimic of CD4, in complex with gp120 (YU2) and 17b);1GC1(gp120 core complexed with CD4 and 17b);1G9M(gp120 (HXB2) complexed with CD4 and 17b);1RZJ(gp120 (HXB2) complexed with CD4 and 17b);2NY1(gp120 (I109C, T257S, S334A, S375W, Q428C) complexed with CD4 and 17b);2NY3(gp120 (K231C, T257S, E267C, S334A, S375W) complexed with CD4 and 17b);2NY4(gp120 (K231C, T257S, E268C, S334A, S375W) complexed with CD4 and 17b);2NY6(gp120 (M95W, W96C, I109C, T123C, T257S, V275C,S334A, S375W, Q428C, G431C) complexed with CD4 and 17b);2NY5(gp120 (M95W, W96C, I109C, T257S, V275C, S334A, S375W, Q428C, A433M) complexed with CD4 and 17b);2NY0(gp120 (M95W, W96C, T257S, V275C, S334A, S375W, A433M) complexed with CD4 and 17b);2NXY(gp120 (S334A) complexed with CD4 and 17b);2NY2(gp120 (T123C, T257S, S334A, S375W, G431C) complexed with CD4 and 17b);2NXZ(gp120 (T257S, S334A, S375W) complexed with CD4 and 17b);1RZK(gp120 (YU2) complexed with CD4 and 17b);1G9N(gp120 (YU2) complexed with CD4 and 17b);4JM2(PGT 135 Fab in complex with gp120 core (JR-FL) bound to CD4 and 17b Fab);2I60([Phe23]M47, a scorpion-toxin mimic of CD4, in complex with gp120 (YU2) and 17b)	N70 			17b contacts	Gorny2009(18952295) 		1-69		1								 
1B2530	gp120 CD4BS	4YFL(1B2530 in complex with HIV-1 clade AE 93TH057 gp120)	Patient 1 		Scheid2011(21764753) 	1B2530 contacts	Scheid2011(21764753) 		1-46	6-13 or 6-19	4 or 5	16	AEAASDSHSRPIMFDH	1-47	3	11	ATYDSDGSIRL	L	 1B2530 is a close clonal relative to INC127, and the germline repertoir is as shown for INC127 in Scheid2011.
1B5	gp120 V2-CD4BS				Strokappe2012(22438910) 														llama antibody 
1C2	gp120 V2-CD4BS				Strokappe2012(22438910) 														llama antibody 
1E1	gp120 V2-CD4BS				Strokappe2012(22438910) 														llama antibody 
1E2	gp120 V2-CD4BS				Strokappe2012(22438910) 														llama antibody 
1F10	gp120 V2-CD4BS				Strokappe2012(22438910) 														llama antibody 
1F7	gp120 CD4BS				Buchacher1994(7520721) 														 
1H9	gp120 V2-CD4BS				Strokappe2012(22438910) 														llama antibody 
1NC9	gp120 CD4BS		Patient 1 		Scheid2011(21764753) 		Scheid2011(21764753) 		1-46	5-12 or 2-8	4 or 5	19	QDSDFHDGHGHTLRGMFDS	1-47	3	11	AAYDSTFSLPV	L	 
2158	gp120 V2	4OAW(Fab structure of V2 mAb 2158)																	 
2191	gp120 V3				Gorny2002(12186887) 														 
2219	gp120 V3	2B0S(antibody 2219 in complex with three different V3 peptides);2B1A(Fab 2219 in complex with UG1033 peptide);2B1H(Fab 2219 in complex with UG29 peptide)			Gorny2002(12186887) 														 
2557	gp120 V3	3MLV(Fab 2557 in complex with an NOF V3 peptide);3MLR(Fab 2557 in complex with a NY5 V3 peptide);3MLT(Fab 2557 in complex with a UG1033 V3 peptide);3MLU(Fab 2557 in complex with a ZAM18 V3 peptide);3MLS(FAb 2557 in complex with gp120 V3 mimotope)			Gorny2004(14963135) 		Andrabi2013(23466102) 	IMGT/V-QUEST	5-51*01		3*01		TRLYLFEGAQSSNAFDL	3-1*01	3*02		QAWDASTGV	L	 
2558	gp120 V3	3UJI(Fab 2558 in complex with MN peptide)			Gorny2004(14963135) 		Andrabi2013(23466102) 	IMGT/V-QUEST	5-51*03		4*02		ARLGFEGDYSGSFFDY	3-1*01	2*01 or 3*01		QAWDSTLGVV	L	 
2909	quaternary structure	3PIQ(2909 Fab)			Gorny2005(15795308) 														 
2D4	gp120 V2-CD4BS				Strokappe2012(22438910) 														llama antibody 
2E7	gp120 V2-CD4BS				Strokappe2012(22438910) 														llama antibody 
2F5	gp41 MPER (membrane proximal external region)	1TJG(2F5 complexed with gp41 7mer epitope);2F5B(2F5 complexed with gp41 epitope);2PR4(2F5 Fab);3BQU(2F5 Fab-3H6 Fab Complex);3MOD(2F5 Fab fragment with 11 aa gp41 MPER-derived peptide);3MOB(2F5 Fab fragment with 11 aa gp41 MPER-derived peptide);3MOA(2F5 Fab fragment with 17 aa gp41 MPER-derived peptide);3IDI(2F5 Fab fragment with gp41 Peptide ALDKWNQ);3IDM(2F5 Fab fragment with gp41 Peptide analog ELD(Nrg)WAS);3IDJ(2F5 Fab fragment with gp41 Peptide analog ELD(Orn)WAS);3IDN(2F5 Fab fragment with gp41 Peptide analog ELD(Paf)WAS);1TJH(2F5 with a gp41 11mer epitope);1TJI(2F5 with a gp41 17mer epitope);3LEV(2F5 with epitope scaffold ES2);3D0L(2F5 with gp41 FP-MPER Hyb3K construct);3DRQ(2F5 with gp41 FP-MPER Hyb3K construct soaked in PEG/2-propanol);1U8H(2F5 with gp41 Peptide ALDKWAS);3IDG(2F5 with gp41 Peptide ALDKWD);1U92(2F5 with gp41 Peptide Analog E-[Dap]-DKWQS (cyclic));1U91(2F5 with gp41 Peptide Analog ENDKW-[Dap]-S (cyclic));1U8P(2F5 with gp41 Peptide ECDKWCS);1U8O(2F5 with gp41 Peptide ELDKHAS);1U8J(2F5 with gp41 Peptide ELDKWAG);1U8I(2F5 with gp41 Peptide ELDKWAN);2PW2(2F5 with gp41 Peptide ELDKWKSL);2PW1(2F5 with gp41 Peptide ELDKWNSL);1U8Q(2F5 with gp41 Peptide ELEKWAS);3DRO(2F5 with gp41 peptide ELLELDKWASLWN);2P8L(2F5 with gp41 Peptide ELLELDKWASLWN);2P8M(2F5 with gp41 Peptide ELLELDKWASLWN in new crystal form);2P8P(2F5 with gp41 Peptide LELDKWASLW[N-Ac]);3D0V(2F5 with gp41 Peptide LLELDKWASLW);3DRT(2F5 with gp41 scrambledFP-MPER scrHyb3K construct);3EGS(2F5 with gp41 scrambledFP-MPER scrHyb3K construct soaked in ammonium sulfate);2F5A(Fab 2F5)		2F5	Buchacher1994(7520721) 	2F5 contacts;2F5 signature predictions (West2013);Mutation affects 2F5 binding	Kunert1998(9737583) 		2		6							K	 
							Zhu2011(21880764) 		2-5*10					1-13*02					
2G12	gp120 carbohydrates at glycosylation residues in C2, C3, C4, and V4;gp120 V3	4RBP(2G12 in complex with a bacterial oligosaccharide analog of mammalian oligomanose);3OAU(2G12 Recognizes Di-Mannose);1OM3(Fab 2G12);1OP3(Fab 2G12 bound to disaccharide mannose);1OP5(Fab 2G12 bound to oligosaccharide mannose);1ZLS(Fab 2G12 + Man4);1ZLU(Fab 2G12 + Man5);1ZLV(Fab 2G12 + Man7);1ZLW(Fab 2G12 + Man8);2OQJ(Fab 2G12 with 21-mer peptide ligand);3OB0(Mimic of the HIV glycan shield);3OAZ(Mimic of the HIV glycan shield);3OAY(Mimic of the HIV glycan shield)		2G12	Buchacher1994(7520721) 	2G12 contacts;2G12 signature predictions (West2013)	Huber2010(20702640) 	IMGT/V-QUEST	3-21	6-25	3			1-5	1			K	 
							Wu2011(21835983) 	IgBlast	3-21*01 or 3-21*02 or 3-21*02 or 3-21*02					1-5*03					
2N5			Donor N152 	35O22	Huang2014(25186731) 		Huang2014(25186731) 	IMGT/V-QUEST	1-18*02	5-24*01	4*02 or 4*03	16	GLLRDGSSTWLPYL	2-14*02	1*01	10	CSYTHNSGCV	L	 
3019	gp120 V3						Andrabi2013(23466102) 	IMGT/V-QUEST	5-51*03		3*01		ARVEGDWGALDL	3-1*01	2*01 or 3*01		QAWDSSSAWGV	L	 
3074	gp120 V3	3MLX(Fab 3074 in complex with an MN V3 peptide);3MLY(Fab 3074 in complex with a UR29 V3 peptide);3MLZ(Fab 3074 in complex with a VI191 V3 peptide)			Gorny2006(16809292) 		Andrabi2013(23466102) 	IMGT/V-QUEST	4-59*01		3*01		ARDFGEYHYDGRGFQCEGFDL	1-51*02	2*01 or 3*01		ATWDGSLRTV	L	 
35O22	gp41-gp120 quartenary interface	4TOY(35O22 Fab);5FYL(Clade A BG505 SOSIP.664 Prefusion Env Trimer in Complex with PGT122 and 35O22);5FYJ(Clade G X1193.c1 SOSIP.664 Prefusion Env Trimer in Complex with PGT122, 35O22 and VRC01);4TVP(Env Trimer Ectodomain in Complex with Antibodies PGT122 and 35O22);5FYK(SOSIP.664 Prefusion Env Trimer in Complex with PGT122, 35O22 and VRC01)	Donor N152 	35O22	Huang2014(25186731) 	35O22 contacts and mutagenesis	Huang2014(25186731) 	IMGT/V-QUEST	1-18*02	5-24*01	4*03 or 4*02	16	GLLRDGSSTWLPYL	2-14*02 or 2-23*03 or 2-23*02 or 2-23*01	1*01	10	CSYTHNSGCV	L	 
3694	gp120 V3				Gorny2009(18952295) 		Andrabi2013(23466102) 	IMGT/V-QUEST	5-51*03		1*01		VRLGHSDIGTSSGDVHN	3-1*01	2*01 or 3*01		QAWDTNTGVH	L	 
3791	gp120 V3				Gorny2009(18952295) 		Andrabi2013(23466102) 	IMGT/V-QUEST	1-18*01		4*02		VRVRDNEQGDYGQLDL	1-1	4*01		QQYESLPWA	K	 
3869	gp120 V3				Gorny2009(18952295) 		Andrabi2013(23466102) 	IMGT/V-QUEST	1-f*01		4*02		ATSHCPGGSCSSSFDF	3-1*01	2*01 or 3*01		QVWDTTTTSYVI	L	 
3881	gp120 V3				Gorny2009(18952295) 		Andrabi2013(23466102) 	IMGT/V-QUEST	4-59*01		3*02		ARISVVVLPAVFPDI	3-15*01	1*01		QQYHDWLWT	K	 
3904	gp120 V3						Andrabi2013(23466102) 	IMGT/V-QUEST	3-30*03		4*03		AKAGEGVGVMDA	1-39*01	3*01		QQSYITIT	K	 
3906	gp120 V3				Gorny2009(18952295) 		Andrabi2013(23466102) 	IMGT/V-QUEST	5-51*01		3*02		ATMTITIGEEFANAFDI	3-1*01	2*01 or 3*01		QAWDRISAV	L	 
3BC176	gp120 CD4BS	5AWN(3BC176 Fab)	Patient 3 		Klein2012(22826297) 	3BC176 and 3BC315 key sites	Klein2012(22826297) 		1-2	5-12	2	19	SMRPVDHGIDYSGLFVFHF	2-23	3	10	CSYASYDRLI	L	 
3BC315	gp120 close to CD4i;gp120 close to V3	5CCK(3BC315 Fab)	Patient 3 		Klein2012(22826297) 	3BC176 and 3BC315 key sites	Klein2012(22826297) 		1-2	5-12	3	19	PMRPVSHGIDYSGLFVFQF	2-23	3	10	CCSYANYDKL	L	 
3BNC117	gp120 CD4BS	4JPV(3BNC117 complexed with gp120);4LSV(3BNC117 complexed with gp120 (C1086))	Patient 3 	3BNC117	Scheid2011(21764753) 	3BNC117 alanine scanning;3BNC117 contacts;3BNC117 signature predictions (West2013);Sites selected during 3BNC117 immunotherapy	Scheid2011(21764753) 		1-2	6-25 or 2-8	2 or 6	10	QRSDYWDFDV	1D-33	3	5	QVYEF	K	 
							Zhou2013a(23911655) 	IgBlast IMGT/V-QUEST	1-02*02			10	QRSDYWDFDV	1-33*01	3*01	5	QVYEF		
3BNC117/10-1074	gp120 CD4BS;gp120 V3		Donor 17 Patient 3 		Bournazos2016(27315478) 														bispecific 
3BNC117/10-1074-IgG3C	gp120 V3;gp41-gp120 quartenary interface		Donor 17 Patient 3 		Bournazos2016(27315478) 														bispecific; IgG3C hinge variant 
3BNC117-IgG3C	gp120 CD4BS		Patient 3 		Bournazos2016(27315478) 														IgG3C hinge variant 
3BNC117/PGT135-IgG3C	gp120 CD4BS;gp41-gp120 quartenary interface		Donor 39 Patient 3 		Bournazos2016(27315478) 														bispecific; IgG3C hinge variant 
3BNC55	gp120 CD4BS		Patient 3 	3BNC117	Scheid2011(21764753) 	3BNC55 signature predictions (West2013)	Scheid2011(21764753) 		1-2	3-3 or 6-19 or 5-12	2 or 6	10	RHSDYCDFDI	1D-33	1 or 3	5	QVYEF	K	 
3BNC60	gp120 CD4BS	4GW4(3BNC60 Fab with P61A mutation);3RPI(Fab 3BNC60)	Patient 3 	3BNC117	Scheid2011(21764753) 	3BNC60 contacts	Scheid2011(21764753) 		1-2	6-25 or 3-3	2 or 6	10	QRSDFWDFDV	1D-33	3	5	QVYEF	K	 3BNC60 is a close clonal relative of 3BNC23, 3BNC128, 3BNC64, 3BNC34, and the germline repertoir is as shown for 3BNC23 in Scheid2011.
							Zhou2013a(23911655) 	IgBlast IMGT/V-QUEST						1-33*01	3*01	5	QVYEF		
3BNC62	gp120 CD4BS		Patient 3 	3BNC117	Scheid2011(21764753) 		Scheid2011(21764753) 		1-2	6-25 or 6-13 or 6-6	2 or 6	10	QRSDYWDFDV	1D-33	3	5	QVYEF	K	 
3E3	gp120 CD4BS				McCoy2014a(25522326) 														llama antibody 
4022	gp120 V3				Gorny2009(18952295) 		Andrabi2013(23466102) 	IMGT/V-QUEST	5-51*01		5*02		ARTGGPEGGGWFEP	3-10*01	3*02		YSTDSRGTYGV	L	 
4025	gp120 V3	3UJJ(Fab 4025 in complex with Con A)			Gorny2009(18952295) 		Andrabi2013(23466102) 	IMGT/V-QUEST	5-51*01		6*02		AILGFWGANRGGGGMDV	3-10*01	1*01		YSTNSGGTFFV	L	 
4121	gp120 V3						Andrabi2013(23466102) 	IMGT/V-QUEST	1-18*01		4*02		AISPLQLERLEDYFDY	1-44*01	1*01		AAWDDSLNGPFV	L	 
4139	gp120 V3				Andrabi2013(23466102) 		Andrabi2013(23466102) 	IMGT/V-QUEST	1-8*01		4*02		ARLTVDCDDGGCYGDY	2-14*01	2*01 or 3*01		NSYRSDTLV	L	 
4210	gp120 V3				Andrabi2013(23466102) 		Andrabi2013(23466102) 	IMGT/V-QUEST	1-f*01		3*02		AIGKSVAGTSAYDI	3-1*01	3*02		QAWDSRAAV	L	 
447-52D	gp120 V3	3C2A(447-52D in complex with UG1033 peptide);1Q1J(Fab 447-52D in complex with V3 peptide);3GHB(Fab 447-52D in complex with V3 peptide 92RW020);4M1D(Fab 447-52D with V3 cyclic peptide MN)			Buchbinder1992(1466965) 														 
4487	gp120 V3				Andrabi2013(23466102) 		Andrabi2013(23466102) 	IMGT/V-QUEST	5-51*03		4*02		ARLDGNAAAFDY	1-51*02	2*01 or 3*01		GTWDNNLRAG	L	 
4490	gp120 V3				Andrabi2013(23466102) 		Andrabi2013(23466102) 	IMGT/V-QUEST	5-51*01		4*02		ARVGYDSYGYSGSNFDE	3-1*01	2*01 or 3*01		QAWDTRTVV	L	 
4508	gp120 V3				Andrabi2013(23466102) 		Andrabi2013(23466102) 	IMGT/V-QUEST	4-59*01		4*02		ARGPLLYFGAPRTHFDY	4-1*01	3*01		QQYYNTPPT	K	 
45-46m2	gp120 CD4BS	4JKP(45-46m2 complexed with gp120)	NIH45 	VRC01 	Diskin2013(23712429) 	45-46m2 signature predictions (West2013)													 
45-46m25	gp120 CD4BS		NIH45 	VRC01 	Diskin2013(23712429) 														 
45-46m28	gp120 CD4BS		NIH45 	VRC01 	Diskin2013(23712429) 														 
45-46m7	gp120 CD4BS		NIH45 	VRC01 	Diskin2013(23712429) 	45-46m7 signature predictions (West2013)													 
4E10	gp41 MPER (membrane proximal external region)	4XCE(4E10 Fab crystalized in the presence of Phosphatidylcholine; C2 space group);4XCC(4E10 Fab crystalized in the presence of Phosphatidylcholine; I422 space group);4XBP(4E10 Fab crystalized in the presence of Phosphatidylethanolamine);4NHC(4E10 Fab fragment in complex with a hydrocarbon-stapled peptide containing the 4e10 epitope on gp41);4NGH(4E10 Fab fragment in complex with a hydrocarbon-stapled peptide containing the 4e10 epitope on gp41 and a tethered phosphate moiety);4XAW(4E10 Fab in complex with its peptide epitope on HIV-1 gp41: Crystals cryoprotected with phosphatidic acid);4XCF(4E10 Fab in complex with its peptide epitope on HIV-1 gp41; crystals cryoprotected with phosphatidylcholine);4XC3(4E10 Fab in complex with its peptide epitope on HIV-1 gp41; crystals cryoprotected with rac-glycerol 1-phosphate);4XC1(4E10 Fab in complex with its peptide epitope on HIV-1 GP41: crystals cryoprotected with sn-Glycerol 3-phosphate);4XBE(4E10 Fab in complex with its peptide epitope on HIV-1 gp41: crystals cryoprotected with sphingomyelin);4XBG(4E10 Fab in complex with phosphatidic acid: 2.73 A resolution);4XCN(4E10 Fab in complex with phosphatidic acid; 2.9 A resolution);4XCY(4E10 Fab in complex with phosphatidylglycerol);4ODX(4E10 germline encoded precursor no.7 in complex with epitope scaffold T117);3H3P(Epitope-scaffold 4E10 Fv complex);1TZG(Fab 4E10 complexed with gp41 13mer epitope);2FX8(Fab 4E10 complexed with gp41 Aib-induced peptide);2FX7(Fab 4E10 complexed with gp41 epitope);2FX9(Fab 4e10 with 4e10 epitope on gp41);5CIN(non-neutralizing version of 4E10 (DeltaLoop) with epitope bound);5CIL(non-neutralizing version of 4E10 (WDWD) with epitope bound);4OB5(Ontogeny of recognition specificity and functionality for 4E10);4M62(Ontogeny of recognition specificity and functionality for 4E10);4LRN(Ontogeny of recognition specificity and functionality for 4E10);4M8Q(Ontogeny of recognition specificity and functionality for 4E10);4WY7(recombinant 4E10 expressed in Escherichia coli with epitope bound);5CIP(Unbound 4E10);4LLV(Unbound form of 4E10 Fv)		4E10	Buchacher1994(7520721) 	4E10 contacts;4E10 signature predictions (West2013);Mutation affects 4E10 binding	Kunert2004(15307922) 		1-69	3-16 or 6-19				A27				L	 
							Morris2011(21980336) 	SoDA	1-69*10		1*01	20		3-20*01		9			
4O20			Donor N152 	35O22	Huang2014(25186731) 		Huang2014(25186731) 	IMGT/V-QUEST	1-18*02	5-24*01	4*02 or 4*03	16	GLLRDGSSTWLPYL	2-14*02	1*01	10	CSYTHNSGCV	L	 
697-D	gp120 V2	4D9L(Fab structure of V2 mAb 697)			Gorny1994(7525987) 														 
7B9			Donor N152 	35O22	Huang2014(25186731) 		Huang2014(25186731) 	IMGT/V-QUEST	1-18*02	5-24*01	4*02 or 4*03	16	GLLRDGSSTWLPYL	2-14*02	1*01	10	CSYTHNSGCV	L	 
7H6			Donor N152 	10E8	Huang2012a(23151583) 		Huang2012a(23151583) 	IMGT/V-QUEST	3-15*05	3-3*01	1*01	22	TGKYYDFWSGYPPGEEYFQD	3-19*01	3*02	12	SSRDKSGSRLSV	L	 
7K3			Donor N152 	35O22	Huang2014(25186731) 		Huang2014(25186731) 	IMGT/V-QUEST	1-18*02	5-24*01	4*02 or 4*03	16	GLLRDGSSTWLPHL	2-14*02	1*01	10	CSYTHNSGCV	L	 
830A	gp120 V2	4YWG(830A in complex with V1V2)			Nyambi2000(10888650) 														 
8ANC131	gp120 CD4BS	4RWY(8ANC131 in complex with HIV-1 clade B YU2 gp120)	Patient 8 		Scheid2011(21764753) 	8ANC131 contacts	Scheid2011(21764753) 		1-46	3-16	6	16	DGLGEVAPDYRYGIDV	3-11	2 or 3	9	QEYSSTPYN	K	 
							Zhou2015(26004070) 	IMGT/V-QUEST	1-46					3-20					
8ANC134	gp120 CD4BS	4RX4(8ANC134 in complex with HIV-1 clade A Q842.d12 gp120)	Patient 8 	8ANC131	Scheid2011(21764753) 	8ANC134 contacts	Scheid2011(21764753) 		1-46	D3-16	6	16	DGLGEVAPAYLYGIDA	3-11	2 or 3	9	QEYSSTPYN	K	 8ANC134 is a close clonal relative of 8ANC26, and the repertoir is as shown for 8ANC26 in Scheid2011.
8ANC195	gp120 CD4BS;gp41-gp120 quartenary interface	4P9M(8ANC195 Fab);5CJX(8ANC195 Fab in complex with BG505 SOSIP.664 HIV-1 Env trimer);4P9H(8ANC195 Fab in complex with gp120 of 93TH057 HIV-1 and soluble CD4 D1D2);5VIY(BG505 SOSIP.664 in complex with antibodies BG1 and 8ANC195);5C7K(BG505 SOSIP gp140 HIV-1 Env trimer bound to broadly neutralizing antibodies PGT128 and 8ANC195);5A8H(cryo-ET subtomogram averaging of BG505 SOSIP.664 in complex with sCD4, 17b, and 8ANC195);5A7X(negative stain EM of BG505 SOSIP.664 in complex with sCD4, 17b, and 8ANC195)	Patient 8 		Scheid2011(21764753) 	8ANC195 contacts;8ANC195 contacts;8ANC195 residue prediction;8ANC195 signature predictions (West2013)	Scheid2011(21764753) 		1-69	3-3		20	TSTYDQWSGLHHDGVMAFSS	1-5	1 or 5	9	QQYDTYPGT	K	 8ANC195 is a close clonal relative of 8ANC142, and the repertoir is shown for 8ANC142 in Scheid2011.
8ANC195-IgG3C	gp120 V3		Patient 8 		Bournazos2016(27315478) 														IgG3C hinge variant 
8ANC195/PGT128-IgG3C	gp120 V3;gp41-gp120 quartenary interface		Donor 36 Patient 8 		Bournazos2016(27315478) 														bispecific; IgG3C hinge variant 
A12	gp120 CD4BS				Forsman2008(18842738) 														llama antibody 
A14	gp120 CD4BS				McCoy2014a(25522326) 														llama antibody 
A16	gp120 CD4BS		F524 		Qiao2016(27387828) 	A16 contacts													 
ACS202	gp41-gp120 quartenary interface	EMD-8299(AMC011 SOSIP trimer in complex with autologous antibody ACS202)	D12950 		vanGils2016(27841852) 	Mutation affects ACS202 neutralization	vanGils2016(27841852) 	IMGT/V-QUEST	3-30*03	2-8*02	6*02	24	CARDRLGRPWNIGGRLVYYYYGMDVW	1-33*01	3*01	9	QEYENLQFT	K	 
b12	gp120 CD4BS	1N0X(B12 complexed with mimotope);1HZH(B12 unliganded);3RU8(Fab b12 with epitope scaffold);2NY7(gp120 complexed with Fab b12)	Donor b 	b12	Burton1991(1719545) 	b12 contacts;b12 signature sites;IGg1b12 signature predictions (West2013);Mutation affects PGV04, b12, VRC01, CD4-IgG neutralization	Wu2010(20616233) 	IMGT/V-QUEST JoinSolver	1-03*01	3-10*02	6*03	20		3-20*01	2*01	9		K	 
b13	gp120 CD4BS	3IDX(gp120 core in complex with b13);3IDY(gp120 core in complex with b13)	Donor b 		Burton1991(1719545) 														 
B21	gp120 CD4BS				McCoy2014a(25522326) 														 
B9	gp120 CD4BS				McCoy2014a(25522326) 														 
BG1	gp120 V1-V2	5VIY(BG505 SOSIP.664 in complex with antibodies BG1 and 8ANC195)	EB354 		Freund2017(28100831) 		Freund2017(28100831) 	IMGT/V-QUEST	3-49			22	EQRNKDYRYGQEGFGYSYGMDV	1-39				K	 
BG18	gp120 V3		EB354 	BG18	Freund2017(28100831) 		Freund2017(28100831) 	IMGT/V-QUEST	4-4			21	NAIRIYGVVALGEWFHYGMDV	3-25		11	QSSDTSDSYKM	L	 
BG8			EB354 	BG18	Freund2017(28100831) 		Freund2017(28100831) 	IMGT/V-QUEST	4-4			21	NVIRVFGFISLGEWFHYGMDV	3-25		11	QSSDTSDSYKM	L	 
C8	gp120 CD4BS				Forsman2008(18842738) 														llama antibody 
CAP257-RH1	gp120 CD4BS	5T33(CAP257-RH1 in complex with strain RHPA gp120 core with an oligomannose N276 glycan)	CAP257 		Wibmer2016(27581986) 		Wibmer2016(27581986) 	IMGT/V-QUEST	3-33*03		6*03	11	AGGGKYDYLDV	3-10*01	3*02	11	FSTDSSGQTWV	L	 
CD4-Ig																			 
CH01	gp120 V2;quaternary structure		CH0219 	CH01	Bonsignori2011(21795340) 	Mutation affects PG9-like Ab sensitivity;PG9-like antibodies require N160 for neutralization;PG9-like contacts	Bonsignori2011(21795340) 	SoDA	3-20	3-10	2	24		3-20	1	9		K	 
							Doria-Rose2014(24590074) 	IMGT/V-QUEST	3-20*01					3-20*01					
CH02	gp120 V2;quaternary structure		CH0219 	CH01	Bonsignori2011(21795340) 	Mutation affects PG9-like Ab sensitivity;PG9-like contacts	Bonsignori2011(21795340) 	SoDA	3-20	3-10	2	24		3-20	1	9		K	 
							Doria-Rose2014(24590074) 	IMGT/V-QUEST	3-20*01					3-20*01					
CH03	gp120 V2;quaternary structure	5ESV(CH03 in Complex with Scaffolded Trimeric HIV-1 Env V1V2 Domain from Clade C Superinfecting Strain of Donor CAP256)	CH0219 	CH01	Bonsignori2011(21795340) 	Mutation affects PG9-like Ab sensitivity;PG9-like contacts	Bonsignori2011(21795340) 	SoDA	3-20	3-10	2	24		3-20	1	9		K	 
							Doria-Rose2014(24590074) 	IMGT/V-QUEST	3-20*01					3-20*01					
CH04	gp120 V2;quaternary structure	3TCL(Antibody CH04);5ESZ(CH04 in Complex with Scaffolded Trimeric HIV-1 Env V1V2 Domain from the Clade AE Strain A244)	CH0219 	CH01	Bonsignori2011(21795340) 	Mutation affects PG9-like Ab sensitivity;PG9-like contacts	Bonsignori2011(21795340) 	SoDA	3-20	3-10	2	24		3-20	1	9		K	 
							Doria-Rose2014(24590074) 	IMGT/V-QUEST	3-20*01					3-20*01					
CH103	gp120 CD4BS	4JAM(antibody CH103);4JAN(CH103 in complex with HIV-1 gp120)	Donor CH505 	CH103	Liao2013(23552890) 	CH103 and CH235 evolution;CH103 contacts & bonding;Selected sites in donor CH505	Liao2013(23552890) 	IMGT/V-QUEST	4-59*01	3-16*01	4*02	15		3-1*01	1*01	10		L	 
CH104	gp120 CD4BS		Donor CH505 	CH103	Liao2013(23552890) 		Liao2013(23552890) 	IMGT/V-QUEST	4-59*01	3-16*01	4*02	15		3-1*01	1*01	10		L	 
CH105	gp120 CD4BS		Donor CH505 	CH103	Liao2013(23552890) 		Liao2013(23552890) 	IMGT/V-QUEST	4-59*01	3-16*01	4*02	15		3-1*01	1*01	10		L	 
CH106	gp120 CD4BS		Donor CH505 	CH103	Liao2013(23552890) 		Liao2013(23552890) 	IMGT/V-QUEST	4-59*01	3-16*01	4*02	15		3-1*01	1*01	10		L	 
CH12	gp41 MPER (membrane proximal external region)		CAP206 		Morris2011(21980336) 		Morris2011(21980336) 	SoDA	1-69*04		6*03	17		3-20*01		11		L	 
CH13	gp120 CD4BS		CH0457 	CH13	Moody2015(26355218) 														 
CH14	gp120 V3		CH0457 		Moody2015(26355218) 														 
CH16	gp120 CD4BS		CH0457 	CH13	Moody2015(26355218) 														 
CH17	gp120 CD4BS		CH0457 	CH13	Moody2015(26355218) 														 
CH18	gp120 CD4BS		CH0457 	CH13	Moody2015(26355218) 														 
CH235	gp120 CD4BS	EMD-8083(B41 SOSIP.664 trimer in complex with CH235 Fab);EMD-8082(BG505 SOSIP.664 in complex with CH235 Fab);5F9W(CH235 in complex with HIV-1 clade AE 93TH057 gp120)	Donor CH505 	CH235	Gao2014(25065977) 	CH103 and CH235 evolution;Selected sites in donor CH505	Bonsignori2016(26949186) 	Cloanalyst	1-46*01	3-10*01	4*02	15	CARNVATEGSLLHYDYW	3-15*01	1*01	8	QYNNWWTF	K	 
CH235.12	gp120 CD4BS	EMD-8079(B41 SOSIP.664 trimer in complex with CH235.12 Fab);EMD-8078(BG505 SOSIP.664 trimer in complex with CH235.12 Fab);5F96(CH235.12 in complex with HIV-1 clade AE 93TH057 gp120)	Donor CH505 	CH235	Bonsignori2016(26949186) 	Electrostatic interactions with D368;Selected sites in donor CH505	Bonsignori2016(26949186) 	Cloanalyst	1-46*01	3-10*01	4*02	15	CVRNVGTAGSLLHYDHW	3-15*01	1*01	8		K	 
CH235.9	gp120 CD4BS	EMD-8080(B41 SOSIP.664 trimer in complex with CH235.9 Fab);EMD-8081(BG505 SOSIP.664 trimer in complex with CH235.9 Fab);5F9O(CH235.09 in complex with HIV-1 clade AE 93TH057 gp120)	Donor CH505 	CH235	Bonsignori2016(26949186) 	Electrostatic interactions with D368;Selected sites in donor CH505	Bonsignori2016(26949186) 	Cloanalyst	1-46*01	3-10*01	4*02	15	CVRNVGTAGSLLHYDHW	3-15*01	1*01	8		K	 
CH27	gp120 CD4BS		CH0457 	CH27	Moody2015(26355218) 														 
CH28	gp120 CD4BS		CH0457 	CH27	Moody2015(26355218) 														 
CH44	gp120 CD4BS		CH0457 	CH27	Moody2015(26355218) 														 
CH45	gp120 CD4BS		CH0457 	CH13	Moody2015(26355218) 														 
CH48	gp120 V3		CH0457 		Moody2015(26355218) 														 
CH98	gp120 CD4BS		CH5329 		Bonsignori2014(24614107) 		Bonsignori2014(24614107) 	SoDA	3-20	1-IR1	4	21		I2-23	3	12		L	 
D7	gp120 CD4BS				Forsman2008(18842738) 														 
DH270.1	gp120 V3	5U0U(DH270.1 (unliganded, single-chain Fv))	CH848 	DH270	Bonsignori2017(28298420) 		Bonsignori2017(28298420) 	Cloanalyst	1-2*02	3-22*01	4*02	20	TTGGWIGLYSDTSGYPNFDY	2-23*02	2*01	10	CSYAGSSIIF	L	 
DH270.2	gp120 V3		CH848 	DH270	Bonsignori2017(28298420) 		Bonsignori2017(28298420) 	Cloanalyst	1-2*02	3-22*01	4*02	20	AKAGYIALYVDYSGYPNFNS	2-23*02	2*01	10	CSYAGSSTVI	L	 
DH270.3	gp120 V3	5TPL(DH270.3 (unliganded))	CH848 	DH270	Bonsignori2017(28298420) 		Bonsignori2017(28298420) 	Cloanalyst	1-2*02	3-22*01	4*02	20	ARGGWISLYVDYSYYPNFDS	2-23*02	2*01	10	SSSTNSATVI	L	 
DH270.4	gp120 V3		CH848 	DH270	Bonsignori2017(28298420) 		Bonsignori2017(28298420) 	Cloanalyst	1-2*02	3-22*01	4*02	20	VTGGWISPYYDSSYYPNFDH	2-23*02	2*01	10	CSFGGSATVV	L	 
DH270.5	gp120 V3	5TPP(DH270.5 (unliganded))	CH848 	DH270	Bonsignori2017(28298420) 		Bonsignori2017(28298420) 	Cloanalyst	1-2*02	3-22*01	4*02	20	VTGAWISDYYDSSYYPNFDH	2-23*02	2*01	10	CSFGGSAAVV	L	 
DH270.6	gp120 V3	5TQA(DH270.6 (unliganded))	CH848 	DH270	Bonsignori2017(28298420) 		Bonsignori2017(28298420) 	Cloanalyst	1-2*02	3-22*01	4*02	20	TTGGWISGYYDSSYYPNFDH	2-23*02	2*01	10	CSFGGSATVV	L	 
DH270.IA1	gp120 V3		CH848 	DH270	Bonsignori2017(28298420) 		Bonsignori2017(28298420) 	Cloanalyst	1-2*02	3-22*01	4*02	20	VTGGWISPYYDSSYYPNFDH	2-23*02	2*01	10	CSFGGSATVV	L	 
DH270.IA2	gp120 V3		CH848 	DH270	Bonsignori2017(28298420) 		Bonsignori2017(28298420) 	Cloanalyst	1-2*02	3-22*01	4*02	20	ATGGWIGLYYDSSGYPNFDY	2-23*02	2*01	10	CSYAGSSTVI	L	 
DH270.IA3	gp120 V3		CH848 	DH270	Bonsignori2017(28298420) 		Bonsignori2017(28298420) 	Cloanalyst	1-2*02	3-22*01	4*02	20	ARGGWIGLYVDYSGYPNFDS	2-23*02	2*01	10	CSYAGSSTVI	L	 
DH270.IA4	gp120 V3		CH848 	DH270	Bonsignori2017(28298420) 		Bonsignori2017(28298420) 	Cloanalyst	1-2*02	3-22*01	4*02	20	ARGGWIGLYYDSSGYPNFDY	2-23*02	2*01	10	CSYAGSSTVI	L	 
DH511.1	gp41 MPER (membrane proximal external region)	5U3J(DH511.1 Fab in Complex with HIV-1 gp41 MPER Peptide)	CH0210 	DH511	Williams2017(28783671) 		Williams2017(28783671) 	IMGT/V-QUEST	3-15*01	3-3*01	6*04	24	TADLGEPVVSRFFEWGSYYYYMDL	1-39*01	2*01	11	QEAYSSTPTLT	K	 
DH511.11P	gp41 MPER (membrane proximal external region)	5U3M(DH511.11P Fab in Complex with HIV-1 gp41 MPER Peptide)	CH0210 	DH511	Williams2017(28783671) 		Williams2017(28783671) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	23	TADEGAPILRFFEWGYYNYYMDV	1-39*01	2*01	11	QESYSSVPMYI	K	 
DH511.12P	gp41 MPER (membrane proximal external region)	5U3N(DH511.12P Fab in Complex with HIV-1 gp41 MPER Peptide)	CH0210 	DH511	Williams2017(28783671) 		Williams2017(28783671) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	23	TADEGAPILRFFEWGYYNYYMDV	1-39*01	2*01	11	QESYSSVPMYI	K	 
DH511.2	gp41 MPER (membrane proximal external region)	5U3K(DH511.2 Fab in Complex with HIV-1 gp41 MPER 662-683 Peptide);5U3L(DH511.2 Fab in Complex with HIV-1 gp41 MPER 670-683 Peptide)	CH0210 	DH511	Williams2017(28783671) 		Williams2017(28783671) 	IMGT/V-QUEST	3-15*01	4-4*01	6*03	23	TMDEGTPVTRFLEWGYFYYYMAV	1-39*01	2*03	11	QENYNTIPSLS	K	 
DH511.2_K3	gp41 MPER (membrane proximal external region)	5U3O(DH511.2_K3 Fab in Complex with HIV-1 gp41 MPER Peptide)	CH0210 	DH511	Williams2017(28783671) 		Williams2017(28783671) 	IMGT/V-QUEST	3-15*01	4-4*01	6*03	23	TMDEGTPVTRFLEWGYFYYYMAV	1-39*01	2*01	11	QESYSSTPTHI	K	DH511.2_K3 is a chimeric Ab: heavy chain from DH511.2 + light chain from DH511.8P 
DH511.3	gp41 MPER (membrane proximal external region)		CH0210 	DH511	Williams2017(28783671) 		Williams2017(28783671) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	24	TADLGEAVVSRFFEWGSYYYYMDF	1-39*01	2*01	11	QEAYSSTPTLT	K	 
DH511.4	gp41 MPER (membrane proximal external region)	5U3P(DH511.4 Fab)	CH0210 	DH511	Williams2017(28783671) 		Williams2017(28783671) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	23	TRDEGAPVTRFLEWGSYYYYMAV	1-39*01	2*01	11	QEAYNTNPTLS	K	 
DH511.5	gp41 MPER (membrane proximal external region)		CH0210 	DH511	Williams2017(28783671) 		Williams2017(28783671) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	23	TRDEGAPVTRFLEWGSYYYYMAV	1-39*01	2*01	11	QEAYNTYPTLS	K	 
DH511.6	gp41 MPER (membrane proximal external region)		CH0210 	DH511	Williams2017(28783671) 		Williams2017(28783671) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	24	ARGTGVVVGGSWTVPPGMAYYLDV	1-39*01	2*03	11	QEAYSSTPTLS	K	 
DH517	gp41 MPER (membrane proximal external region)		CH0210 		Williams2017(28783671) 		Williams2017(28783671) 	IMGT/V-QUEST	4-34*01	3-16*01	6*01	24	ARGTGVVVGGSWTVPPGMAYYLDV	3-39*01	2*01	12	ASRDRSGDRLGV	L	 
DH563	gp120 V3		CH765 	VRC41	Alam2017(28298421) 		Alam2017(28298421) 	Cloanalyst IMGT/V-QUEST	4-39	3-3	4-1	21		3-20	4	9		K	 
DRVIA7	gp120 CD4BS	5CD3(Immature VRC01-class antibody DRVIA7);5CD5(Immature VRC01-class antibody DRVIA7 bound to clade A/E HIV-1 gp120 core)	DRVI01 		Kong2016(27067056) 														 
F105	gp120 CD4BS	1U6A(Fab F105);3HI1(gp120 (core with V3) complex with F105)			Posner1991(1710248) 														 
gVRC-H1dC38-VRC01L	gp120 CD4BS		C38 NIH45 		Zhu2013a(24106303) 														 
HGN194	gp120 V3		VI3265 		Corti2010(20098712) 														 
HJ16	gp120 CD4BS	4YE4(Neutralizing Antibody HJ16 in Complex with HIV-1 gp120)	VI3208 		Corti2010(20098712) 	HJ16 binding requires N276;HJ16 contacts	Wu2011(21835983) 	IgBlast	3-30*18					4-1*01				K	 
HK20	gp41 NHR (N-heptad repeat)	2XRA(HK20 Fab in complex with a gp41 mimetic 5-Helix)	VI3081 		Corti2010(20098712) 														 
IOMA	gp120 CD4BS	5T3Z(Fully and Natively Glycosylated BG505 SOSIP.664 HIV-1 Env Trimer in Complex with Antibodies IOMA and 10-1074);5T3X(Fully and Natively Glycosylated BG505 SOSIP.664 HIV-1 Env Trimer in Complex with Antibodies IOMA and 10-1074)	R1 		Gristick2016(27617431) 		Gristick2016(27617431) 	IgBlast	1-2*02			16	EMFDSSADWSPWRGMVA	2-23*02		8	YSYADGVAF	L	 
J3	gp120 CD4BS				McCoy2012(22641382) 														llama antibody 
JM2	gp120 CD4BS				Matz2013(23152508) 														llama antibody 
JM3	gp120-CD4 complex				Matz2013(23152508) 														llama antibody 
JM4	gp120 CD4BS;gp120 CD4i	4LAJ(JM4 in complex with YU2 gp120 and CD4-mimetic miniprotein M48U1)			Matz2013(23152508) 														llama antibody 
JM4-IgG2b	gp120 CD4BS;gp120 CD4i				Acharya2013(23843638) 														llama antibody 
JM4-IgG3	gp120 CD4BS;gp120 CD4i				Acharya2013(23843638) 														llama antibody 
JM5	gp120-CD4 complex				Matz2013(23152508) 														llama antibody 
KD-247	gp120 V3	3NTC(KD-247 Fab)			Eda2006a(16699036) 														mouse antibody 
m66	gp41 MPER (membrane proximal external region)	4NRY(Antibody m66);4NRX(m66 in complex with gp41 MPER peptide)	SC44 		Zhu2011(21880764) 		Ofek2014(24335316) 		5-51*01	3-10*01	6*02			1-39*01	3*01			K	 
m66.6	gp41 MPER (membrane proximal external region)	4NRZ(Antibody m66.6)	SC44 		Zhu2011(21880764) 		Ofek2014(24335316) 		5-51*01	3-10*01	6*02			I1-39*01	3*01			K	 
m66-G30K	gp41 MPER (membrane proximal external region)		SC44 		Ofek2014(24335316) 														 
m66-S28H	gp41 MPER (membrane proximal external region)		SC44 		Ofek2014(24335316) 														 
m66-S28H-G30K	gp41 MPER (membrane proximal external region)		SC44 		Ofek2014(24335316) 														 
m66-S28H-G30K-S31K	gp41 MPER (membrane proximal external region)		SC44 		Ofek2014(24335316) 														 
m66-S31K	gp41 MPER (membrane proximal external region)		SC44 		Ofek2014(24335316) 														 
m66-Y100eW	gp41 MPER (membrane proximal external region)		SC44 		Ofek2014(24335316) 														 
N6	gp120 CD4BS	5TE5(N6 in Complex with HIV-1 Clade AE Strain 93TH057 gp120 Core);5TE6(N6 in Complex with HIV-1 Clade C Strain DU172.17 gp120 Core);5TE4(N6 in Complex with HIV-1 Clade G Strain X2088 gp120 Core)	Z258 		Huang2016a(27851912) 	N6 alanine scanning;N6 contacts	Huang2016a(27851912) 	IMGT/V-QUEST	1-2*02	2-21*02	6*01	13	CARDRSYGDSSWALDAWGQGTTVVVSA	1-33*01 or 1D-33*01	5*01	5	QVLQF	K	 
NC37	quaternary structure		EB354 		Freund2017(28100831) 		Freund2017(28100831) 	IMGT/V-QUEST	1-2 or 1-46			19	DNFGTRPVPGRGYYYGMDV	3-20				K	 
NIH45-46	gp120 CD4BS	4JDT(chimeric germ-line precursor of NIH45-46 Fab in complex with gp120 (93TH057));3U7W(Fab NIH45-46);3U7Y(Fab NIH45-46 complexed with gp120);4JDV(germ-line precursor of NIH45-46 Fab);5IGX(NIH45-46 Fab germline precursor in complex with 426c.TM1deltaV1-3 gp120)	NIH45 	VRC01 	Scheid2011(21764753) 	NIH45-46 contacts;NIH45-46 signature predictions (West2013)	Zhou2013a(23911655) 	IgBlast IMGT/V-QUEST	1-02*02			16	GKYCTARDYYNWDFEH	3-20*01	2*01	5	QQYEF	K	 
							Scheid2011(21764753) 		1-2					3-11					
NIH45-46G54F	gp120 CD4BS		NIH45 	VRC01	Diskin2011(22033520) 														 
NIH45-46G54W	gp120 CD4BS		NIH45 	VRC01 	Diskin2011(22033520) 	NIH45-46(G54W) signature predictions (West2013)													 
NIH45-46G54Y	gp120 CD4BS		NIH45 	VRC01	Diskin2011(22033520) 														 
PCDN-33A	gp120 V3		PC76 		MacLeod2016(27192579) 	Sites affecting neutralization of PCDN lineage mAbs													 
PCDN-38A	gp120 V3		PC76 		MacLeod2016(27192579) 	Sites affecting neutralization of PCDN lineage mAbs	Longo2016(27654288) 	IMGT/V-QUEST JoinSolver	4-34*01		5*01	22	ARGGRKICYDYWCGYVNNCFDT	3-20*01	1*01	8	QQCGSSPT	K	 
PCDN-38B	gp120 V3		PC76 		MacLeod2016(27192579) 	Sites affecting neutralization of PCDN lineage mAbs													 
PCT64-18B	gp120 V2		PC64 	PCT64	Landais2017(29166592) 		Landais2017(29166592) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	25	MTGVETKDFWGDDYGDYYDHYFIDV	3-20*01	3*01	8	RQYDTSFT	K	 
PCT64-18C	gp120 V2		PC64 	PCT64	Landais2017(29166592) 		Landais2017(29166592) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	25	MTGVETGDFWSDDYANYYDPYLIDV	3-20*01	3*01	8	RQYGTSFT	K	 
PCT64-18D	gp120 V2		PC64 	PCT64	Landais2017(29166592) 		Landais2017(29166592) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	25	MTGVETGDFWSDYYAQYYDPYLIDV	3-20*01	3*01	8	RQYGTSFT	K	 
PCT64-18F	gp120 V2		PC64 	PCT64	Landais2017(29166592) 		Landais2017(29166592) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	25	MTGVETGDFWSDYYAQYYDPYLIDV	3-20*01	3*01	8	RQYGTSFT	K	 
PCT64-24A	gp120 V2		PC64 	PCT64	Landais2017(29166592) 		Landais2017(29166592) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	25	NTGVESYDFWSDDYSQYQYKYFWDV	3-20*01	3*01	8	QQYTSSCT	K	 
PCT64-24B	gp120 V2		PC64 	PCT64	Landais2017(29166592) 		Landais2017(29166592) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	25	NTGVESYDFWSDDYSQYQYKYFWDV	3-20*01	3*01	8	QQYTSSCT	K	 
PCT64-24E	gp120 V2		PC64 	PCT64	Landais2017(29166592) 		Landais2017(29166592) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	25	NTGVESYDFWSDDYSQYDYTYLSDV	3-20*01	3*01	8	QQYSSSCT	K	 
PCT64-24F	gp120 V2		PC64 	PCT64	Landais2017(29166592) 		Landais2017(29166592) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	25	MTGVETGDFWSDEYSQHYDPYLIDV	3-20*01	3*01	8	RQYDRSFT	K	 
PCT64-24G	gp120 V2		PC64 	PCT64	Landais2017(29166592) 		Landais2017(29166592) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	25	MTGVETGDFWSDDYSQHYNSYLIDV	3-20*01	3*01	8	RQYDTSFT	K	 
PCT64-24H	gp120 V2		PC64 	PCT64	Landais2017(29166592) 		Landais2017(29166592) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	25	MTGVETGDFWSDDYSQHYNSYLIDV	3-20*01	3*01	8	RQYDTSFT	K	 
PCT64-35B	gp120 V2	5FEH(PCT64_35B, a broadly neutralizing anti-HIV antibody)	PC64 	PCT64	Landais2017(29166592) 		Landais2017(29166592) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	25	MTGVEKGDFWSDDYSQHYNTYLIDV	3-20*01	3*01	8	RQYETSFS	K	 
PCT64-35C	gp120 V2		PC64 	PCT64	Landais2017(29166592) 		Landais2017(29166592) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	25	MTGVEKGDFWSDDYSQHYNTYLIDV	3-20*01	3*01	8	RQYETSFT	K	 
PCT64-35D	gp120 V2		PC64 	PCT64	Landais2017(29166592) 		Landais2017(29166592) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	25	MTGVEKGDFWSDDYSQHYNTYLIDV	3-20*01	3*01	8	RQYETSFT	K	 
PCT64-35E	gp120 V2		PC64 	PCT64	Landais2017(29166592) 		Landais2017(29166592) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	25	MTGVEKGDFWSDDYSQHYNTYLIDV	3-20*01	3*01	8	RQYETSFT	K	 
PCT64-35F	gp120 V2		PC64 	PCT64	Landais2017(29166592) 		Landais2017(29166592) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	25	MTGVEKGDFWSDDYSQHYNTYLIDV	3-20*01	3*01	8	RQYDTSFT	K	 
PCT64-35G	gp120 V2		PC64 	PCT64	Landais2017(29166592) 		Landais2017(29166592) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	25	MTGVEKGDFWSDDYSQHYNTYLIDV	3-20*01	3*01	8	RQYETSFS	K	 
PCT64-35H	gp120 V2		PC64 	PCT64	Landais2017(29166592) 		Landais2017(29166592) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	25	MTGVERGDFWSDDYSQHYNTYLIDV	3-20*01	3*01	8	RQYDTSFT	K	 
PCT64-35I	gp120 V2		PC64 	PCT64	Landais2017(29166592) 		Landais2017(29166592) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	25	MTGVERGGFWSDEYSQHWDPYLIDV	3-20*01	3*01	8	RQYDTSFT	K	 
PCT64-35K	gp120 V2		PC64 	PCT64	Landais2017(29166592) 		Landais2017(29166592) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	25	MTGVEAGDFWSDEYSQHYNTYLIDV	3-20*01	3*01	8	RQYETSFT	K	 
PCT64-35M	gp120 V2		PC64 	PCT64	Landais2017(29166592) 		Landais2017(29166592) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	25	NTGVEWYDFWSDEYSQEETKYFKDV	3-20*01	3*01	8	QQYTRSCT	K	 
PCT64-35N	gp120 V2		PC64 	PCT64	Landais2017(29166592) 		Landais2017(29166592) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	25	MTGVEAGDFWSDEYSQHYNTYLIDV	3-20*01	3*01	8	RQYDTSFT	K	 
PCT64-35O	gp120 V2		PC64 	PCT64	Landais2017(29166592) 		Landais2017(29166592) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	25	MTGVEAGDFWSDEYSQHYNTYLIDV	3-20*01	3*01	8	RQYDTSFT	K	 
PCT64-35S	gp120 V2		PC64 	PCT64	Landais2017(29166592) 		Landais2017(29166592) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	25	MTGVERGDFWSDDYSQHYNTYLIDV	3-20*01	3*01	8	RQYETSFT	K	 
PG16	gp120 V2;quaternary structure	4DQO(Fab PG16 complexed with V1V2 region (ZM109));3MUG(PG16 Fab);3MME(Structure and functional dissection of PG16);3LRS(Structure of PG16)	Donor 24 	PG9	Walker2009a(19729618) 	Mutation affects PG9-like Ab sensitivity;PG16 signature predictions (West2013);PG9-like antibodies require N160 for neutralization;PG9-like contacts	Pancera2010(20538861) 	IMGT/V-QUEST JoinSolver	3-33*05	3-3*01	6*03			2-14*01	3*02			L	 
							Walker2009a(19729618) 	IMGT/V-QUEST	3-33*05				EAGGPIWHDDVKYYDFNDGYYNYHYMDV	2-14*01			SSLTDRSHRIF		
PG16/10-1074	gp120 V1-V2;gp120 V3		Donor 17 Donor 24 		Bournazos2016(27315478) 														bispecific 
PG16-iMab			Donor 24 		Pace2013a(23878231) 														bispecific 
PG16/PGT121	gp120 V1-V2;gp120 V3		Donor 17 Donor 24 		Bournazos2016(27315478) 														bispecific 
PG16/PGT128	gp120 V1-V2;gp120 V3		Donor 24 Donor 36 		Bournazos2016(27315478) 														bispecific 
PG9	gp120 V2;quaternary structure	3U36(Fab PG9  );3U4E(Fab PG9 complexed with V1V2 region (CAP45));3U2S(Fab PG9 complexed with V1V2 region (ZM109));3MUH(PG9 light chain)	Donor 24 	PG9	Walker2009a(19729618) 	Mutation affects PG9-like Ab sensitivity;PG9 escape mutations;PG9-like antibodies require N160 for neutralization;PG9-like contacts;PG9 residue prediction;PG9 signature predictions (West2013)	Pancera2010(20538861) 	IMGT/V-QUEST JoinSolver	3-33*05	3-3*01	6*03			2-14*01	3*02			L	 
							Walker2009a(19729618) 	IMGT/V-QUEST	3-33*05				EAGGPDYRNGYNYYDFYDGYYNYHYMDV	2-14*01			KSLTSTRRRVF		
PG9-iMab			Donor 24 		Pace2013a(23878231) 														bispecific 
PG9-PG16-RSH	gp120 V2		Donor 24 	PG9	Pancera2013(23708607) 		Pancera2010(20538861) 	IMGT/V-QUEST	3-33*05	3-3*01	6*03			2-14*01	3*02			L	chimeric 
PGC14			Donor 24 		Walker2009a(19729618) 		Walker2009a(19729618) 	IMGT/V-QUEST	1-24*01				GAVGADSGSWFDP	3-1*01			AWETTTTTFVFF	L	 
PGDM11	gp120 V3		Donor 14 		Sok2016(27438765) 														 
PGDM12	gp120 V3		Donor 14 		Sok2016(27438765) 														 
PGDM1400	gp120 V2	4RQQ(Fab PGDM1400)	Donor 84 		Sok2014(25422458) 	PGDM1400 lineage requires N160	Sok2014(25422458) 	IMGT/V-QUEST	1-8		6	34	CAKGSKHRLRDYALYDDDGALNWAVDVDYLSNLEFW	2-28	1	9	CMQGRESPWTF	K	 
PGDM1401	gp120 V2		Donor 84 		Sok2014(25422458) 	PGDM1400 lineage requires N160	Sok2014(25422458) 	IMGT/V-QUEST	1-8		6	34	CARGSKHRLRDYVMYDDYGALQWAVYVDYLSNLDVW	2-28	1	9	CMQGRESPWTF	K	 
PGDM1402	gp120 V2		Donor 84 		Sok2014(25422458) 	PGDM1400 lineage requires N160	Sok2014(25422458) 	IMGT/V-QUEST	1-8		6	34	CAKGSKHRLRDYALYDDIGALQWAVDVDYLSTLEFW	2-28	1	9	CMQGRESPWTF	K	 
PGDM1403	gp120 V2		Donor 84 		Sok2014(25422458) 	PGDM1400 lineage requires N160	Sok2014(25422458) 	IMGT/V-QUEST	1-8		6	33	CVKGSKFRLREWADYNEWGLVSAQHGDYVTQLGIW	2-28	1	9	CMQGLQSPTTF	K	 
PGDM1404	gp120 V2		Donor 84 		Sok2014(25422458) 	PGDM1400 lineage requires N160	Sok2014(25422458) 	IMGT/V-QUEST	1-8		6	34	CVRGAKFRLRHDATYDYWNDLLWADDRDYVTQLDLW	2-28	1	9	CMQGRHIPLTF	K	 
PGDM1405	gp120 V2		Donor 84 		Sok2014(25422458) 	PGDM1400 lineage requires N160	Sok2014(25422458) 	IMGT/V-QUEST	1-8		6	34	CVRGAKFRLRHDATYDYYNDLLWADDRDYVTQLDLW	2-28	1	9	CMQGRHIPLTF	K	 
PGDM1406	gp120 V2		Donor 84 		Sok2014(25422458) 	PGDM1400 lineage requires N160	Sok2014(25422458) 	IMGT/V-QUEST	1-8		1	33	CVKGQKFRLTEWADYNEFGLVAAQKGDYVTQLDVW	2-28	1	9	CMQGLRTPMTF	K	 
PGDM21	gp120 V3	EMD-8182(PGDM21 in complex with BG505 SOSIP.664 trimer)	Donor 82 		Sok2016(27438765) 														 
PGT121	gp120 V3	4JY4(Fab PGT121);4FQQ(germline antibody PGT121-GL Fab);4FQ1(PGT121 Fab);4FQC(PGT121 Fab bound to a complex-type sialylated N-glycan)	Donor 17 	PGT121	Walker2011(21849977) 	Key sites for PGT121-like and 10-1074-like mAbs;PGT121-123, 125-128, 130, 131 sites important for neutralization;PGT121 family and N137 glycan;PGT121 signature predictions (West2013)	Sok2013(24278016) 	IMGT/V-QUEST	4-59		6*03	26	CARTLHGRRIYGIVAFNEWFTYFYMDVW	3-21	3*02	15	DYYCHIWDSRVPTKWVF	L	 CDR3 sequences are longer in Sok2013 than reported in Walker2011.
							Walker2011(21849977) 	IMGT/V-QUEST SoDA2	4-59*01		6*03	24	TLHGRRIYGIVAFNEWFTYFYMDV	3-21*02	3*02	12	HIWDSRVPTKWV		
PGT122	gp120 V3	4NCO(BG505 in complex with Fab PGT122);5I8H(BG505 SOSIP.664 Prefusion Env Trimer in Complex with PGT122 Fab and VRC34.01 Fab);5FYL(Clade A BG505 SOSIP.664 Prefusion Env Trimer in Complex with PGT122 and 35O22);5FYJ(Clade G X1193.c1 SOSIP.664 Prefusion Env Trimer in Complex with PGT122, 35O22 and VRC01);4TVP(Env Trimer Ectodomain in Complex with Antibodies PGT122 and 35O22);4JY5(Fab PGT122);5FYK(SOSIP.664 Prefusion Env Trimer in Complex with PGT122, 35O22 and VRC01)	Donor 17 	PGT121	Walker2011(21849977) 	PGT121-123, 125-128, 130, 131 sites important for neutralization;PGT121 family and N137 glycan	Sok2013(24278016) 	IMGT/V-QUEST	4-59		6*03	26	CATTKHGRRIYGVVAFKEWFTYFYMDVW	3-21	3*02	15	DYYCHIWDSRRPTNWVF	L	 CDR3 sequences are longer in Sok2013 than reported in Walker2011.
							Walker2011(21849977) 	IMGT/V-QUEST SoDA2	4-59*01		6*03	24	TKHGRRIYGVVAFKEWFTYFYMDV	3-21*02	3*02	12	HIWDSRRPTNWV		
PGT123	gp120 V3	4JY6(Fab PGT123)	Donor 17 	PGT121	Walker2011(21849977) 	PGT121-123, 125-128, 130, 131 sites important for neutralization;PGT121 family and N137 glycan	Sok2013(24278016) 	IMGT/V-QUEST	4-59		6*03	26	CARALHGKRIYGIVALGELFTYFYMDVW	3-21	3*02	15	DYYCHIYDARGGTNWVF	L	 CDR3 sequences are longer in Sok2013 than reported in Walker2011.
							Walker2011(21849977) 	IMGT/V-QUEST SoDA2	4-59*01		6*03	24	ALHGKRIYGIVALGELFTYFYMDV	3-21*02	3*02	12	HIYDARGGTNWV		
PGT124	gp120 V3		Donor 17 	PGT121	Walker2011(21849977) 	PGT121 family and N137 glycan	Sok2013(24278016) 	IMGT/V-QUEST	4-59		6*03	26	CATARRGWRIYGVVSFGEFFYYYYMDVW	3-21	3*02	15	DYYCHMWDSRSGFSWSF	L	 
PGT125	gp120 V3		Donor 36 	PGT128	Walker2011(21849977) 	PGT121-123, 125-128, 130, 131 sites important for neutralization	Walker2011(21849977) 	IMGT/V-QUEST SoDA2	4-39*07		5*02	19	FDGEVLVYNHWPKPAWVDL	2-8*01	2*01 or 3*01	10	GSLVGNWDV	L	 
PGT126	gp120 V3		Donor 36 	PGT128	Walker2011(21849977) 	PGT121-123, 125-128, 130, 131 sites important for neutralization	Walker2011(21849977) 	IMGT/V-QUEST SoDA2	4-39*07		5*02	19	FDGEVLVYHDWPKPAWVDL	2-8*01	2*01 or 3*01	10	SSLVGNWDVI	L	 
PGT127	gp120 V3	3TWC(PGT127 complexed with Man(9))	Donor 36 	PGT128	Walker2011(21849977) 	PGT121-123, 125-128, 130, 131 sites important for neutralization;PGT127, PGT128 contacts	Walker2011(21849977) 	IMGT/V-QUEST SoDA2	4-39*07		5*02	19	FGGEVLVYRDWPKPAWVDL	2-8*01	2*01 or 3*01	10	SSLVGNWDV	L	 
PGT128	gp120 V3	5C7K(BG505 SOSIP gp140 HIV-1 Env trimer bound to broadly neutralizing antibodies PGT128 and 8ANC195);3TYG(PGT128 complexed with glycosylated gp120);3TV3(PGT128 complexed with Man(9));5ACO(PGT128 Fab in complex with BG505 SOSIP.664 Env trimer)	Donor 36 	PGT128	Walker2011(21849977) 	PGT121-123, 125-128, 130, 131 sites important for neutralization;PGT127, PGT128 contacts;PGT128 contacts	Walker2011(21849977) 	IMGT/V-QUEST SoDA2	4-39*07		5*02	19	FGGEVLRYTDWPKPAWVDL	2-8*01	2*01 or 3*01	10	GSLVGNWDVI	L	 
PGT128-IgG3C	gp120 V3		Donor 36 		Bournazos2016(27315478) 														IgG3C hinge variant 
PGT130	gp120 V3		Donor 36 	PGT128	Walker2011(21849977) 	PGT121-123, 125-128, 130, 131 sites important for neutralization	Walker2011(21849977) 	IMGT/V-QUEST SoDA2	4-39*07		5*02	19	SGGDILYYYEWQKPHWFSP	2-8*01	2*01 or 3*01	10	SSLFGRWDVV	L	 
PGT131	gp120 V3		Donor 36 	PGT128	Walker2011(21849977) 	PGT121-123, 125-128, 130, 131 sites important for neutralization	Walker2011(21849977) 	IMGT/V-QUEST SoDA2	4-39*07		5*02	19	SGGDILYYIEWQKPHWFYP	2-8*01	2*01 or 3*01	10	SSLSGRWDIV	L	 
PGT135	gp120 V3	4JM4(Fab PGT135);4JM2(PGT 135 Fab in complex with gp120 core (JR-FL) bound to CD4 and 17b Fab)	Donor 39 	PGT135	Walker2011(21849977) 	PGT135 contacts and sites	Walker2011(21849977) 	IMGT/V-QUEST SoDA2	4-39*07		5*02	18	HRHHDVFMLVPIAGWFDV	3-15*01	1*01	9	QQYEEWPRT	K	 
PGT135-IgG3C	gp120 V3		Donor 39 		Bournazos2016(27315478) 														IgG3C hinge variant 
PGT136	gp120 V3		Donor 39 	PGT135	Walker2011(21849977) 		Walker2011(21849977) 	IMGT/V-QUEST SoDA2	4-39*07		5*02	18	HKYHDIFRVVPVAGWFDP	3-15*01	1*01	9	QQYEEWPRT	K	 
PGT137	gp120 V3		Donor 39 	PGT135	Walker2011(21849977) 		Walker2011(21849977) 	IMGT/V-QUEST SoDA2	4-39*07		5*02	18	HKYHDIVMVVPIAGWFDP	3-15*01	1*01	9	QQYEEWPRT	K	 
PGT141	gp120 V2;quaternary structure		Donor 84 	PGT145	Walker2011(21849977) 	Mutation affects PG9-like Ab sensitivity;PG9-like contacts	Walker2011(21849977) 	IMGT/V-QUEST SoDA2	1-8*01		6*02	32	GSKHRLRDYVLYDDYGLINYQEWNDYLEFLDV	2-28*01 or 2D-28*01	1*01	9	MQGLNRPWT	K	 
PGT142	gp120 V2;quaternary structure		Donor 84 	PGT145	Walker2011(21849977) 		Walker2011(21849977) 	IMGT/V-QUEST SoDA2	1-8*01		6*02	32	GSKHRLRDYVLYDDYGLINYQEWNDYLEFLDV	2-28*01 or 2D-28*01	1*01	9	MQGLNRPWT	K	 
PGT143	gp120 V2;quaternary structure		Donor 84 	PGT145	Walker2011(21849977) 		Walker2011(21849977) 	IMGT/V-QUEST SoDA2	1-8*01		6*02	32	GSKHRLRDYVLYDDYGLINYQEWNDYLEFLDV	2-28*01 or 2D-28*01	1*01	9	MQGLNRPWT	K	 
PGT144	gp120 V2;quaternary structure		Donor 84 	PGT145	Walker2011(21849977) 		Walker2011(21849977) 	IMGT/V-QUEST SoDA2	1-8*01		6*02	32	GSKHRLRDYVLYDDYGLINQQEWNDYLEFLDV	2-28*01 or 2D-28*01	1*01	9	MQGLNRPWT	K	 
PGT145	gp120 V2;quaternary structure	3U1S(Fab PGT145)	Donor 84 	PGT145	Walker2011(21849977) 	Mutation affects PG9-like Ab sensitivity;PG9-like antibodies require N160 for neutralization;PG9-like contacts;PGT145 escape mutations	Walker2011(21849977) 	IMGT/V-QUEST SoDA2	1-8*01		6*02	31	GSKHRLRDYFLYNEYGPNYEEWGDYLATLDV	2-28*01 or 2D-28*01	1*01	9	MQGLHSPWT	K	 
PGT151	gp41-gp120 quartenary interface	4NUG(Antibody PGT151)	Donor 31 		Falkowska2014(24768347) 	Mutation affects PG151 neutralization;PGT151-PGT158 sites of interaction	Falkowska2014(24768347) 		3-30*04		6*02	28	ARMFQESGPPRLDRWSGRNYYYYSGMDV	2D-29*02	4*01	9	MQSKDFPLT	K	 
PGT151/10-1074-IgG3C	gp120 V3;gp41-gp120 quartenary interface		Donor 17 Donor 31 		Bournazos2016(27315478) 														bispecific; IgG3C hinge variant 
PGT151/35O22	gp41-gp120 quartenary interface		Donor 31 Donor N152 		Bournazos2016(27315478) 														bispecific 
PGT151-IgG3C	gp41-gp120 quartenary interface		Donor 31 		Bournazos2016(27315478) 														IgG3C hinge variant 
PGT152	gp41-gp120 quartenary interface	4NUJ(Antibody PGT152)	Donor 31 		Falkowska2014(24768347) 	PGT151-PGT158 sites of interaction	Falkowska2014(24768347) 		3-30*04		6*02	28	ARMFQESGPPRFDSWSGRNYYYYSGMDV	2D-29*02	4*01	9	MQSKDFPLT	K	 
PGT153	gp41		Donor 31 		Falkowska2014(24768347) 	PGT151-PGT158 sites of interaction	Falkowska2014(24768347) 		3-30*04		6*02	28	ARDRDGYGPPQIQTWSGRYLHLYSGIDA	2D-29*02	4*01	9	MQSKDFPLT	K	 
PGT154	gp41		Donor 31 		Falkowska2014(24768347) 	PGT151-PGT158 sites of interaction	Falkowska2014(24768347) 		3-30*04		6*02	28	ARNIEEFSVPQFDSWSGRSYYHYFGMDV	2D-29*02	4*01	9	MQSRDFPIT	K	 
PGT155	gp41		Donor 31 		Falkowska2014(24768347) 	PGT151-PGT158 sites of interaction	Falkowska2014(24768347) 		3-30*04		6*02	28	AKDGEEHKVPQLHSWSGRNLYHYTGFDV	2D-29*02	4*01	9	LQTKDFPLT	K	 
PGT156	gp41		Donor 31 		Falkowska2014(24768347) 	PGT151-PGT158 sites of interaction	Falkowska2014(24768347) 		3-30*04		6*02	28	AKDGEEHKVPQLHSWSGRNLYHYTGFDV	2D-29*02	4*01	9	LQTKDFPLT	K	 
PGT157	gp41		Donor 31 		Falkowska2014(24768347) 	PGT151-PGT158 sites of interaction	Falkowska2014(24768347) 		3-30*04		6*02	28	AKDGEEHEVPQLHSWSGRNLYHYTGVDI	2D-29*02	4*01	9	MQTKDFPLT	K	 
PGT158	gp41		Donor 31 		Falkowska2014(24768347) 	PGT151-PGT158 sites of interaction	Falkowska2014(24768347) 		3-30*04		6*02	28	AKDGEEHEVPQLHSWSGRNLYHYTGVDV	2D-29*02	4*01	9	MQTKDFPLT	K	 
sCD4		1CDJ(glycoprotein CD4);1GC1(gp120 core complexed with CD4 and 17b);1G9M(gp120 (HXB2) complexed with CD4 and 17b);1RZJ(gp120 (HXB2) complexed with CD4 and 17b);2NY5(gp120 (M95W, W96C, I109C, T257S, V275C, S334A, S375W, Q428C, A433M) complexed with CD4 and 17b);2NY0(gp120 (M95W, W96C, T257S, V275C, S334A, S375W, A433M) complexed with CD4 and 17b);2NXY(gp120 (S334A) complexed with CD4 and 17b);1RZK(gp120 (YU2) complexed with CD4 and 17b);1G9N(gp120 (YU2) complexed with CD4 and 17b)																	 
VRC01	gp120 CD4BS	5FYJ(Clade G X1193.c1 SOSIP.664 Prefusion Env Trimer in Complex with PGT122, 35O22 and VRC01);4JPI(Fab VRC01 germline precursor);5FYK(SOSIP.664 Prefusion Env Trimer in Complex with PGT122, 35O22 and VRC01);3NGB(VRC01 complexed with gp120);4LSS(VRC01 complexed with gp120 (KER2008));4LST(VRC01 complexed with gp120 (ZM176));4JPK(VRC01 germline precursor Fab complexed with gp120 outer domain)	NIH45 	VRC01 	Wu2010(20616233) 	Electrostatic interactions with D368;Mutation affects PGV04, b12, VRC01, CD4-IgG neutralization;Sequence changes after immunotherapy with VRC01;VRC01 alanine scanning;VRC01 contacts;VRC01 residue prediction;VRC01 signature predictions (West2013)	Wu2010(20616233) 	IMGT/V-QUEST JoinSolver	1-02*02	3-16*01 or 3-16*02	1*01 or 2*01	14		3-11*01	2*01	5		K	 Zhou2013 note re-assignment of previously-published germline genes for VRC01 and VRC03.Zhou2013 note re-assignment of previously-published germline genes for VRC01 and VRC03.
							Zhou2013a(23911655) 	IgBlast IMGT/V-QUEST	1-02*02			12	GKNCDYNWDFEH	3-20*01	2*01	5	QQYEF		
VRC01-0fH/0fL	gp120 CD4BS		NIH45 	VRC01	Georgiev2014(24391217) 														 
VRC01-30fH/10fL	gp120 CD4BS		NIH45 	VRC01	Georgiev2014(24391217) 														 
VRC01-30fH/19fL	gp120 CD4BS		NIH45 	VRC01	Georgiev2014(24391217) 														 
VRC01-5fH/0fL	gp120 CD4BS		NIH45 	VRC01	Georgiev2014(24391217) 														 
VRC01-5fH/10fL	gp120 CD4BS		NIH45 	VRC01	Georgiev2014(24391217) 														 
VRC01-5fH/6fL	gp120 CD4BS		NIH45 	VRC01	Georgiev2014(24391217) 														 
VRC01-8fH/10fL	gp120 CD4BS		NIH45 	VRC01	Georgiev2014(24391217) 														 
VRC01-8fH/19fL	gp120 CD4BS		NIH45 	VRC01	Georgiev2014(24391217) 														 
VRC01-8fH/6fL	gp120 CD4BS		NIH45 	VRC01	Georgiev2014(24391217) 														 
VRC02	gp120 CD4BS		NIH45 	VRC01 	Wu2010(20616233) 	VRC02 signature predictions (West2013)	Wu2010(20616233) 	IMGT/V-QUEST JoinSolver	1-02*02	3-16*01 or 3-16*02	1*01 or 2*01	14		3-11*01	2*01	5		K	 
VRC03	gp120 CD4BS	5JXA(Ligand-free VRC03 antigen-binding fragment);3SE8(VRC03 complexed with gp120);5JOF(VRC03 gHVgLV antigen-binding fragment)	NIH45 	VRC01	Wu2010(20616233) 	VRC03 contacts;VRC03 signature predictions (West2013)	Li2012(22875963) 	IMGT/V-QUEST JoinSolver	1-2*02 or 1-2*04	3-22*01	1*01	16		3-20*01	2*01	5		K	 Zhou2013 note re-assignment of previously-published germline genes for VRC01 and VRC03.Zhou2013 note re-assignment of previously-published germline genes for VRC01 and VRC03.
							Wu2010(20616233) 	IMGT/V-QUEST JoinSolver	1-02*02	3	1*01	16		3-20*01	2*01	5			
							Zhou2013a(23911655) 	IgBlast IMGT/V-QUEST	1-02*02			14	RGSCDYCGDFPWQY	3-20*01	2*01	5	QQFEF		
VRC06	gp120 CD4BS	4JB9(VRC06 in complex with HIV-1 gp120 core)	NIH45 	VRC01	Li2012(22875963) 		Li2012(22875963) 	IMGT/V-QUEST JoinSolver	1-2*02 or 1-2*04	4-17*01	1*01	17		3-20*01	2*01	5		K	 
VRC06b	gp120 CD4BS	4XNZ(VRC06B in complex with HIV-1 clade A/E strain 93TH057 gp120)	NIH45 	VRC01	Li2012(22875963) 		Li2012(22875963) 	IMGT/V-QUEST JoinSolver	1-2*02 or 1-2*04	4-17*01	1*01	17		3-20*01	2*01	5		K	 
VRC07	gp120 CD4BS	4OLV(VRC07-G54F in complex with 93TH057 gp120);4OLW(VRC07-G54H in complex with 93TH057 gp120);4OLX(VRC07-G54L in complex with 93TH057 gp120);4OLY(VRC07-G54R in complex with 93TH057 gp120);4OLZ(VRC07-G54W in complex with 93TH057 gp120);4OM0(VRC07-G54Y in complex with 93TH057 gp120);4OM1(VRC07-I30Q, G54W, S58N in complex with 93TH057 gp120);4OLU(VRC07 in complex with 93TH057 gp120)	NIH45 	VRC01	Rudicell2014(25142607) 		Rudicell2014(25142607) 	IMGT/V-QUEST	1-02*02			16	CTRGKYCTARDYYNWDFEH	3-20*01				K	 
VRC07-501-LS	gp120 CD4BS		NIH45 		Rudicell2014(25142607) 														 
VRC07-508-LS	gp120 CD4BS		NIH45 		Rudicell2014(25142607) 														 
VRC07-523-LS	gp120 CD4BS		NIH45 		Rudicell2014(25142607) 														 
VRC07-544-LS	gp120 CD4BS		NIH45 		Rudicell2014(25142607) 														 
VRC07xPG9-16			Donor 24 NIH45 		Asokan2015(26446600) 														bispecific 
VRC13	gp120 CD4BS	4YDJ(44-VRC13.01 in complex with HIV-1 clade AE strain 93TH057 gp120)	44 		Zhou2015(26004070) 	VRC13 contacts	Zhou2015(26004070) 	IMGT/V-QUEST	1-69					2-14				L	 
VRC16	gp120 CD4BS	4YDK(C38-VRC16.01 in complex with HIV-1 clade AE strain 93TH057 gp120)	C38 		Zhou2015(26004070) 	VRC16 contacts	Zhou2015(26004070) 	IMGT/V-QUEST	3-32					1-39				K	 
VRC18	gp120 CD4BS	4YDL(C38-VRC18.02 in complex with HIV-1 clade AE strain 93TH057 gp120)	C38 		Zhou2015(26004070) 	VRC18 contacts	Zhou2015(26004070) 	IMGT/V-QUEST	1-2					3-20				K	 
VRC21.01	gp120 V3		N170 	VRC21	Longo2016(27654288) 		Longo2016(27654288) 	IMGT/V-QUEST JoinSolver	3-30*03		4*02	12	VRGDGENGGTDY	6-57*01	3*02	10	QSYDSNYYWV	L	 
VRC21.02	gp120 V3		N170 	VRC21	Longo2016(27654288) 		Longo2016(27654288) 	IMGT/V-QUEST JoinSolver	3-30*03		4*02	12	VRGDGENGGTDY	6-57*01	3*02	10	QSYDDTYFWV	L	 
VRC22.01	gp120 V3		N170 		Longo2016(27654288) 		Longo2016(27654288) 	IMGT/V-QUEST JoinSolver	4-34*01		6*02	19	ARAGGMSDWAYPYYYGMDV	1-17*01	1*01	9	LQYNTFPRT	K	 
VRC23	gp120 CD4BS	4J6R(VRC23 in complex with HIV-1 gp120)	127/C 		Georgiev2013(23661761) 		Georgiev2013(23661761) 	IMGT/V-QUEST JoinSolver	1-2*02					3-15*01				K	 
VRC23b	gp120 CD4BS		127/C 		Georgiev2013(23661761) 		Georgiev2013(23661761) 	IMGT/V-QUEST JoinSolver	1-2*02					3-15*01				K	 
VRC24	gp120 V3		N27 		Georgiev2013(23661761) 		Georgiev2013(23661761) 	IMGT/V-QUEST JoinSolver	4-4*07					1-51*02				L	 
VRC26.01	gp120 V2;quaternary structure	4OCR(Fab CAP256-VRC26.01)	CAP256 	VRC26	Doria-Rose2014(24590074) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			35	CAKDVGDYKSDEWGTEYYDISISYPIQDPRAMVGAFDLW	51*02				L	 
VRC26.02	gp120 V2;quaternary structure		CAP256 	VRC26	Doria-Rose2014(24590074) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			35	CAKDIREYECEYWTSDYYDFGRPQPCIDSRGVVGTFDVW	51*02				L	 
VRC26.03	gp120 V2;quaternary structure	4OD1(Fab CAP256-VRC26.03)	CAP256 	VRC26	Doria-Rose2014(24590074) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			35	CAKDLREDECEEWWSDYYDFGKQLPCRKSRGVAGIFDGW	51*02				L	 
VRC26.04	gp120 V2;quaternary structure	4ORG(Fab CAP256-VRC26.04)	CAP256 	VRC26	Doria-Rose2014(24590074) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			35	CAKDLREDECEEWWSDYYDFGKQLPCRKSRGVAGIFDKW	51*02				L	 
VRC26.05	gp120 V2;quaternary structure		CAP256 	VRC26	Doria-Rose2014(24590074) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			35	CARDQRYYECEEWASDYYDFGREQPCLDPRGVVGIFDLW	51*02				L	 
VRC26.06	gp120 V2;quaternary structure	4OCW(Fab CAP256-VRC26.06)	CAP256 	VRC26	Doria-Rose2014(24590074) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			36	CARDLRELECEEWTLYNYYDFGSRGPCVDPRGVAGSFDVW	51*02				L	 
VRC26.07	gp120 V2;quaternary structure	4OD3(Fab CAP256-VRC26.07, a potent V1V2-directed HIV-1 neutralizing antibody)	CAP256 	VRC26	Doria-Rose2014(24590074) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			35	CAKDLREDECEEWWSDYYDFGKKLPCRKSRGVAGVFDKW	51*02				L	 
VRC26.08	gp120 V2;quaternary structure		CAP256 	VRC26	Doria-Rose2014(24590074) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			37	CVRDQREDECEEWWSDYYDFGRELPCRKFRGLGLAGIFDIW	51*02				L	 
VRC26.09	gp120 V2;quaternary structure		CAP256 	VRC26	Doria-Rose2014(24590074) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage mutations;CAP256-VRC26 lineage neutralization-associated sites;VRC26.09 escape mutations	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			37	CVKDQREDECEEWWSDYYDFGRELPCRKSRGLGLAGIFDMW	51*02				L	 
VRC26.10	gp120 V2;quaternary structure	4OCS(Fab CAP256-VRC26.10)	CAP256 	VRC26	Doria-Rose2014(24590074) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			35	CAKDMREYECEYWTSDYYDFGRPQPCIDRRGVVGIFDMW	51*02				L	 
VRC26.11	gp120 V2;quaternary structure		CAP256 	VRC26	Doria-Rose2014(24590074) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			35	CVKDMRELECEEWASDYYDFGKPQPCLDRRGVSGISAWW	51*02				L	 
VRC26.12	gp120 V2;quaternary structure		CAP256 	VRC26	Doria-Rose2014(24590074) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			35	CARDLRESECEEWESDYYDFGKKGPCVKPRGVAGGLDLW	51*02				L	 
VRC26.13	gp120 V2;quaternary structure		CAP256 	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			35	CARDLRESECEEWESDYYDFGKKGPCVKPRGVAGGLDLW	51*02				L	 
VRC26.14	gp120 V2;quaternary structure		CAP256 	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			35	CARDVREMECEEWASDYYDFGRGGPCRDFRGVVGILDIW	51*02				L	 
VRC26.15	gp120 V2;quaternary structure		CAP256 	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			35	CARDLREYECELWASDYYDFGKPQPCEDPRGVVGTSDIW	51*02				L	 
VRC26.16	gp120 V2;quaternary structure		CAP256 	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			35	CARDVREMECEEWASDYYDFGRGGPCRDFRGVVGILDIW	51*02				L	 
VRC26.17	gp120 V2;quaternary structure		CAP256 	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			35	CARDMREMECEEWASDYYDFGRPGPCRDLRGVVGTFDIW	51*02				L	 
VRC26.18	gp120 V2;quaternary structure		CAP256 	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			35	CARDMREMECEEWASDYYDFGRSGPCRDFRGVVGVFDIW	51*02				L	 
VRC26.19	gp120 V2;quaternary structure		CAP256 	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			35	CARDSREYECELWTSDYYDFGKPQPCIDTRDVGGLFDMW	51*02				L	 
VRC26.20	gp120 V2;quaternary structure		CAP256 	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			37	CVRDQREDECEERWSDYYHFGRVLPCRKYRGLGLAGVFDIW	51*02				L	 
VRC26.21	gp120 V2;quaternary structure		CAP256 	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			37	CVRDRQEDECEEWWSDYYAFGRGGPCRKYHGQGLAGIFDIW	51*02				L	 
VRC26.22	gp120 V2;quaternary structure		CAP256 	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			37	CVRDRQEDECVEWWSDYYNFGRELPCSKFRGLGLAGIFDIW	51*02				L	 
VRC26.23	gp120 V2;quaternary structure		CAP256 	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			35	CAKDLREYECEEWRSDYYDFGRDQPCIDSQGVVGILDIW	51*02				L	 
VRC26.24	gp120 V2;quaternary structure		CAP256 	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			35	CAKDLGGIKNDEWGTDYYDISVSYPVQDPRAVAGIFDVW	51*02				L	 
VRC26.25	gp120 V2;quaternary structure	5DT1(Fab CAP256-VRC26.25)	CAP256 	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage mutations;CAP256-VRC26 lineage neutralization-associated sites;VRC26.25 neutralization associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			36	CAKDLREDECEEWWSDYYDFGKQLPCAKSRGGLVGIADNW	51*02				L	 
VRC26.26	gp120 V2;quaternary structure		CAP256 	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			37	CVRDQREDECEEWWSDYYDFGKELPCRKFRGLGLAGIFDVW	51*02				L	 
VRC26.27	gp120 V2;quaternary structure		CAP256 	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			37	CVRDQREDECEEWWSDYYDFGKELPCRKFRGLGLAGIFDIW	51*02				L	 
VRC26.28	gp120 V2;quaternary structure		CAP256 	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			37	CVRDRQEDECVEWWSDYYNFGRELPCSKFRGLGLAGIFDIW	51*02				L	 
VRC26.29	gp120 V2;quaternary structure		CAP256 	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			37	CVRDRQEDECVEWWSDYYNFGRELPCSKFRGLGLAGIFDIW	51*02				L	 
VRC26.30	gp120 V2;quaternary structure		CAP256 	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			37	CVRDRQEDECEEWWSDYYNFGRELPCRKFRGQGLAGIFDIW	51*02				L	 
VRC26.31	gp120 V2;quaternary structure		CAP256 	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			37	CVRDRQEDECEEWWSDYYNFGRELPCRKFRGPGLAGIFDIW	51*02				L	 
VRC26.32	gp120 V2;quaternary structure		CAP256 	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			35	CVKDLRELECEEWTSDYYDFGRPQPCIDPRGVSGISAMW	51*02				L	 
VRC26.33	gp120 V2;quaternary structure		CAP256 	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			35	CARDQRYYECEEWASDYYDFGREQPCQDPRGVVGIFDIW	51*02				L	 
VRC27	gp120 CD4BS	4YDI(Z258-VRC27.01 in complex with HIV-1 gp120 from clade A strain Q23.17)	Z258 		Zhou2015(26004070) 	VRC27 alanine scanning;VRC27 contacts	Huang2016a(27851912) 	IMGT/V-QUEST	1-2*02			13	CARDRLYDGSSWRLDPWGQGTRVVVSS	1-33*01		5	QVLES	K	 
VRC28.01	gp120 V3		N170 		Longo2016(27654288) 		Longo2016(27654288) 	IMGT/V-QUEST JoinSolver	4-34*03		4*02	26	VRGHLSRDRLGQYAFWSGALIDYLDP	2-28*01	1*01	9	MQGIDTPRT	K	 
VRC29.01	gp120 V3		N170 	VRC29	Longo2016(27654288) 		Longo2016(27654288) 	IMGT/V-QUEST JoinSolver	4-59*08		3*02	20	ARHRYDRWSDSYDIRSPFDI	3-20*01	1*01	9	HQYDRSPRT	K	 
VRC29.02	gp120 V3		N170 	VRC29	Longo2016(27654288) 		Longo2016(27654288) 	IMGT/V-QUEST JoinSolver	4-59*08		3*02	20	ARHRYDVWSKGYDIRSPFDF	3-20*01	1*01	9	QQFDFSPRT	K	 
VRC29.03	gp120 V3		N170 	VRC29	Longo2016(27654288) 		Longo2016(27654288) 	IMGT/V-QUEST JoinSolver	4-59*08		3*02	20	ARHRYDVWSNGYDIRSPYDF	3-20*01	1*01	9	QQYDFSPRT	K	 
VRC29.04	gp120 V3		N170 	VRC29	Longo2016(27654288) 		Longo2016(27654288) 	IMGT/V-QUEST JoinSolver	4-59*08		3*02	20	ARHRYDPWSKGYDIRSPFDF	3-20*01	1*01	9	EQYDVSPRT	K	 
VRC34.01	gp41 fusion domain	5I8C(BG505 Fusion Peptide in Complex with VRC34.01 Fab);5I8H(BG505 SOSIP.664 Prefusion Env Trimer in Complex with PGT122 Fab and VRC34.01 Fab);5I8E(VRC34.01 Fab)	N123 	VRC34	Kong2016a(27174988) 	VRC34.01 critical residues	Kong2016a(27174988) 	IMGT/V-QUEST	1-2*02		6*02		ARDKYYGNEAVGMDVW	1-9*01	4*01		QHMSSYPLTF	K	 
VRC38.01	gp120 V1-V2	5EWI(Fab VRC38.01);5VGJ(Fab VRC38.01 bound to a scaffolded WITO V1V2 domain)	N90 	VRC38	Cale2017(28514685) 		Cale2017(28514685) 	Cloanalyst IMGT/V-QUEST	3-13*01		6	16	GPESGWFYHYYWGLGV	2-28*01	4	10	MEARQTPRLT	K	 
VRC38.02	gp120 V1-V2		N90 	VRC38	Cale2017(28514685) 		Cale2017(28514685) 	Cloanalyst IMGT/V-QUEST	3-13*01		6	16	GPSSGWHLHYYFGMGL	2-28*01	4	10	MQSLETPRLS	K	 
VRC38.03	gp120 V1-V2		N90 	VRC38	Cale2017(28514685) 		Cale2017(28514685) 	Cloanalyst IMGT/V-QUEST	3-13*01		6	16	GPASGWWYHDYYGLYV	2-28*01	4	10	MQARQTPRLS	K	 
VRC38.04	gp120 V1-V2		N90 	VRC38	Cale2017(28514685) 		Cale2017(28514685) 	Cloanalyst IMGT/V-QUEST	3-13*01		6	16	GPSSGWHLHYYFGMGL	2-28*01	4	10	MQSLETPRLS	K	 
VRC38.05	gp120 V1-V2		N90 	VRC38	Cale2017(28514685) 		Cale2017(28514685) 	Cloanalyst IMGT/V-QUEST	3-13*01		6	16	GPSSGWHLHYYFGMGL	2-28*01	4	10	MQSLETPRLS	K	 
VRC38.06	gp120 V1-V2		N90 	VRC38	Cale2017(28514685) 		Cale2017(28514685) 	Cloanalyst IMGT/V-QUEST	3-13*01		6	16	GPESGWFYHYYFGLGV	2-28*01	4	10	MQARQTPRLS	K	 
VRC38.07	gp120 V1-V2		N90 	VRC38	Cale2017(28514685) 		Cale2017(28514685) 	Cloanalyst IMGT/V-QUEST	3-13*01		6	16	GPESGWFYHYYWGLGA	2-28*01	4	10	MEARQTPRLT	K	 
VRC38.08	gp120 V1-V2		N90 	VRC38	Cale2017(28514685) 		Cale2017(28514685) 	Cloanalyst IMGT/V-QUEST	3-13*01		6	16	GPTSGWWYHDYYGLDV	2-28*01	4	10	MQAVQTPRLS	K	 
VRC38.09	gp120 V1-V2		N90 	VRC38	Cale2017(28514685) 		Cale2017(28514685) 	Cloanalyst IMGT/V-QUEST	3-13*01		6	16	GPSSGWWYHYYFGLHL	2-28*01	4	10	MQARQTPRLS	K	 
VRC38.10	gp120 V1-V2		N90 	VRC38	Cale2017(28514685) 		Cale2017(28514685) 	Cloanalyst IMGT/V-QUEST	3-13*01		6	16	GPMSGWWYHDYYGLDV	2-28*01	4	10	MQAVETPRLS	K	 
VRC38.11	gp120 V1-V2		N90 	VRC38	Cale2017(28514685) 		Cale2017(28514685) 	Cloanalyst IMGT/V-QUEST	3-13*01		6	16	GPTSGWWYHDYYGLDA	2-28*01	4	10	MQAVQTPRLS	K	 
VRC38.12	gp120 V1-V2		N90 	VRC38	Cale2017(28514685) 		Cale2017(28514685) 	Cloanalyst IMGT/V-QUEST	3-13*01		6	16	GPMSGWWYHDYYGLDA						VRC38.12 is an orphan heavy chain; neutralization results were obtained by expressing with the light chain of VRC38.01. 
VRC38.13	gp120 V1-V2		N90 	VRC38	Cale2017(28514685) 		Cale2017(28514685) 	Cloanalyst IMGT/V-QUEST	3-13*01		6	16	GPESGWFYHYYFGLGV						VRC38.13 is an orphan heavy chain; neutralization results were obtained by expressing with the light chain of VRC38.01. 
VRC38.14	gp120 V1-V2		N90 	VRC38	Cale2017(28514685) 		Cale2017(28514685) 	Cloanalyst IMGT/V-QUEST	3-13*01		6	16	GPTSGWWYHQYYGLDV						VRC38.14 is an orphan heavy chain; neutralization results were obtained by expressing with the light chain of VRC38.01. 
VRC41.01	gp120 V3		CH765 	VRC41	Alam2017(28298421) 		Alam2017(28298421) 	Cloanalyst IMGT/V-QUEST	4-39	3-3	4-1	21		3-20	4	9		K	 
VRC41.02	gp120 V3		CH765 	VRC41	Alam2017(28298421) 		Alam2017(28298421) 	Cloanalyst IMGT/V-QUEST	4-39	3-3	4-1	21		3-20	4	9		K	 
VRC-CH30	gp120 CD4BS		CH0219 	VRC-CH31	Wu2011(21835983) 		Wu2011(21835983) 	IMGT/V-QUEST JoinSolver	1-2*02	3-16*01	4*02	15		1-33*01	2*01	5		K	 
VRC-CH31	gp120 CD4BS	4LSP(VRC-CH31 complexed with gp120 (93TH057));4LSQ(VRC-CH31 complexed with gp120 (93TH057/3514 chimera));4LSR(VRC-CH31 complexed with gp120 (93TH057/KER2008 chimera))	CH0219 	VRC-CH31	Wu2011(21835983) 	VRC-CH31 signature predictions (West2013)	Wu2011(21835983) 	IMGT/V-QUEST JoinSolver	1-2*02	3-16*01	4*02	15		1-33*01	2*01	5		K	 
VRC-CH32	gp120 CD4BS		CH0219 	VRC-CH31	Wu2011(21835983) 		Wu2011(21835983) 	IMGT/V-QUEST JoinSolver	1-2*02	3-16*01	4*02	15		1-33*01	2*01	5		K	 
VRC-CH33	gp120 CD4BS		CH0219 	VRC-CH31	Wu2011(21835983) 		Wu2011(21835983) 	IMGT/V-QUEST JoinSolver	1-2*02	3-16*01	4*02	15		1-33*01	2*01	5		K	 
VRC-CH34	gp120 CD4BS		CH0219 	VRC-CH31	Wu2011(21835983) 		Wu2011(21835983) 	IMGT/V-QUEST JoinSolver	1-2*02	3-16*01	4*02	15		1-33*01	2*01	5		K	 
VRC-PG04	gp120 CD4BS	3J5M(BG505 Env trimer with 3 PGV04 Fabs);4I3S(gp120 complexed with VRC-PG04 space group P21);4I3R(gp120 complexed with VRC-PG04 space group P3221);EMD-7107(PC64M4c054 SOSIP in complex with PGV04 Fab);EMD-8302(SOSIP trimer from patient AMC011 in complex with Fab from IgG PGV04);3SE9(VRC-PG04 complexed with gp120)	Donor 74 	VRC-PG04 	Wu2011(21835983) 	Mutation affects PGV04, b12, VRC01, CD4-IgG neutralization;VRC-PG04 alanine scanning;VRC-PG04 contacts;VRC-PG04 signature predictions (West2013)	Mascola2012() 	IMGT/V-QUEST	1-2*02	2-8*02	2*01	16	ARQKFYTGGQGWYFDLWGRGTLIVVSS	3-11*01	5*01	5	QQLEF	K	 
							Wu2011(21835983) 	IMGT/V-QUEST JoinSolver	1-2*02	5-12*01	2*01	16		3-20*01	5*01	5			
VRC-PG04b	gp120 CD4BS		Donor 74 	VRC-PG04 	Wu2011(21835983) 	VRC-PG04b signature predictions (West2013)	Wu2011(21835983) 	IMGT/V-QUEST JoinSolver	1-2*02	5-12*01	2*01	16		3-20*01	5*01	5		K	 
VRC-PG05	gp120 CD4BS		Donor 74 		Mascola2012() 		Mascola2012() 	IMGT/V-QUEST	3-7*01	3-3*01	3*02	19	ARIRQVSKYLQWYPGVFEMWGQGTMVTVSS	4-1*01	2*03	8	QQYFFLYS	K	 
VRC-PG19	gp120 V2-CD4BS		IAVI 23 		Zhou2013a(23911655) 		Zhou2013a(23911655) 	IgBlast IMGT/V-QUEST	1-02*02			11	MGAAREWDFQY	2-14*01	2*01	5	NAYEF	L	 
VRC-PG20	gp120 CD4BS	4LSU(VRC-PG20 in complex with HIV-1 clade A/E 93TH057 gp120)	IAVI 23 		Zhou2013a(23911655) 		Zhou2013a(23911655) 	IgBlast IMGT/V-QUEST	1-02*02			12	RRSQDREWDFQH	2-14*01	2*01	5	NAYEF	L	 
							Zhou2015(26004070) 	IMGT/V-QUEST	1-2					2-14					
Z13e1	gp41 MPER (membrane proximal external region)	3FN0(Fab Z13e1 in complex with a 12-residue peptide containing the Z13e1 epitope on gp41);3Q1S(Z13e1 in complex with epitope display protein)	FDA2 		Nelson2007(17287272) 	Mutation affects Z13e1 binding;Z13e1 contacts	Morris2011(21980336) 	SoDA	4-59*03		6*03	19		3-11*01		9		L	 
